Aspects of genetic and environmental control of phase II metabolism by Fordyce, Karen
        
University of Bath
PHD








Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 23. May. 2019
ASPECTS OF GENETIC AND ENVIRONMENTAL 
CONTROL OF PHASE II METABOLISM
Submitted by KAREN FORDYCE B.Sc. 
for the degree of Ph.D. 
of the University of Bath 
1987
Copyright
Attention is drawn to the fact that copyright of this thesis rests 
with its author. This copy of the thesis has been supplied on 
condition that anyone who consults it is understood to recognise 
that its copyright rests with its author and that no quotation 
from the thesis and no information derived from it may be 
published without the prior.written consent of the author.
This thesis may be made available for consultation within the 
University Library and may be photocopied or lent to other 




INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U545178
Published by ProQuest LLC 2014. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
U M I'"  BATH




To my parents and Adrian * with love and many thanks for their 








1.1 DRUG METABOLISM 1
Phase I Metabolism 2
Phase II Metabolism 3
1.2 FACTORS AFFECTING DRUG METABOLISM 4
a) Genetic Control of Drug Metabolism 6
Polymorphism of Oxidation 7
Polymorphism of Hydrolysis 8
Polymorphism of Acetylation "
The significance of Polymorphism of 9
Oxidation, Hydrolysis and Acetylation
b) Environmental Control lO
Other Drugs or Foreign Compounds ”
Age 11
Sex 12
Disease and Diet M
1.3 ASPIRIN 14
a) Mode of Action and Therapeutic
Uses
Analgesic Effect 14





1.4 METABOLISM OF ASPIRIN
Absorption and Distribution 17
Metabolism and Excretion 19
Pharmacokinetics 1
1.5 PARACETAMOL 21




1.6 METABOLISM OF PARACETAMOL
Absorption and Distribution 23
Metabolism "
Pharmacokinetics 25
1.7 ORAL CONTRACEPTIVE STEROIDS 26












1.8 METABOLISM OF ENDOGENOUS ESTRADIOL 30
Phase I Metabolism of Estradiol M
Phase II Metabolism of Estradiol 32
Enterohepatic Circulation 33
Protein Binding 34
1.9 METABOLISM OF ETHINYL ESTRADIOL 34
Phase I Metabolism 35
Phase II Metabolism 37
Pharmacokinetics of Ethinyl Estradiol 11
1.10 SCOPE OF THE THESIS 39





d) Other Chemicals 44
2.2 INSTRUMENTATION
a) High Performance Liquid Chromato- 45
graphy (HPLC)
b) Liquid Scintillation Counter 47
2.3 HUMAN VOLUNTEERS 48
2.4 ANIMALS 49
2.5 ADMINISTRATION OF DRUGS
a) To Humans 49
b) To Animals 50
Page No.
2.6 STORAGE OF BIOLOGICAL SAMPLES 51
2.7 ANALYSIS OF ASPIRIN METABOLITES 51
HPLC Conditions . 11
Assay Procedure ’*
2.8 ANALYSIS OF PARACETAMOL AND ITS MAJOR
METABOLITES
a) In Urine 52
HPLC Conditions 11
Assay Procedure 55
b) In Serum 55
HPLC Conditions 58
Assay Procedure 58
2.9 ANALYSIS OF 17 -ESTRADIOL
a) In Plasma 58
Assay Procedure 11
Kit Specificity 61
b) In Urine 62
Assay Procedure ”
2.10 DETERMINATION OF RADIOACTIVITY IN 62
BIOLOGICAL SAMPLES
2.11 QUANTITATION OF ASPIRIN METABOLITES,
PARACETAMOL AND ITS METABOLITES AND 
ESTRADIOL IN BIOLOGICAL FLUIDS USING 
STANDARD CURVES
a) Preparation of Standard Curves
Aspirin and Paracetamol Metabolites 64
Estradiol 65
Page No.
b) Linearity of Calibration Curves 65
c) Concentration Determination 66
2.12 STATISTICAL ANALYSIS AND TREATMENT OF 67
DATA




a) Environmental Control of Aspirin 
Metabolism
Effect of Urine pH 70
Correction Method 72
Effect of Age and Weight 73
Effect of Gender ,f
Effect of Smoking and Oral Contra- 76
ceptive Steroids
b) Genetic Control of Aspirin Metabolism 80
Repeat Studies 84
3.4 DISCUSSION 87
Urine pH and Salicylic Acid Excretion "
Body Weight and ASA Metabolism 88
Age and ASA Metabolism 89
Sex Differences and ASA Metabolism 90
Oral Contraceptive Steroids and ASA 91
Metabolism
Page No.
Smoking and ASA Metabolism 92
Genetic Control of Aspirin Metabolism 93




a) Environmental Control of Paracetamol 101
Metabolism
Effect of Age and Weight 104
Effect of Gender "
Effects of Smoking 108
Effect of Oral Contraceptive 110
Steroids
b) Genetic Control of Paracetamol 112
Metabolism
4.4 DISCUSSION
a) Environmental Control of Paracetamol 119
Metabolism
Effect of Age 120
Effect of Body Weight 121
Effect of Gender "
Effect of Smoking 122
Effect of Oral Contraceptive Steroids 123
b) Genetic Control of Paracetamol Metabolism 124
Genetic Control of Glucuronidation 1 25
Genetic Control of Sulphatiori 127
Page No.






CHAPTER SIX: THE EFFECT OF CHRONIC ETHINYLESTRADIOL PRETREATMENT










CHAPTER SEVEN:COMPARISON OF FACTORS AFFECTING GLYCINE, GLUCURONIDE 
AND SULPHATE CONJUGATION
7.1 GENETIC CONTROL OF DRUG METABOLISM 172




d) Oral Contraceptive Steroids 179
Page No.
Animal Studies: Effect of EE^ on Phase II 181
Metabolism





I would like to express my sincere thanks to my supervisors, Dr. 
P.N. Bennett, M.D., F.R.C.P. and Dr. L.J. Notarianni, M.Sc., Ph.D., 
for their continual encouragement and advice throughout this 
project. I also gratefully acknowledge the Science and Engineering 
Research Council for providing the financial support and the School 
of Pharmacy and Pharmacology for the use of its facilities.
I wish to thank Dr. Reid, Sister Humphries and the administrative
and medical staff at the Ministry of Defence bases, Ensleigh and 
Foxhill, for all their invaluable help in recruiting volunteers. I 
also wish to thank Dr. M. Finnen and Dr. R. Taylor for their
technical assistance and helpful advice and Dr. R. Johnson for his
expert assistance in computer graphical analysis. I am also very 
grateful to the staff in the Animal House for their help and 
support.
Finally, I would like to thank all of the volunteers who 
participated in these studies, without whose support this project 
would not have been possible.
ABBREVIATIONS
ASA acetyl salicylic acid





FSH follicle stimulating hormone
HPLC high performance liquid chromatography
LH luteinising hormone







1. The glycine conjugate of salicylic acid (SA) and the 
glucuronide and sulphate conjugates of paracetamol were 
examined in a population of healthy volunteers (n = 150 and 99 
respectively) following therapeutic doses of aspirin (600 mg) and 
paracetamol (1 g). These 2 population studies enabled the genetic 
and environmental effects of three phase II metabolic pathways 
(glycine, glucuronide and sulphate conjugations) to be 
investigated.
A significant relationship between urine pH and SA excretion was 
noted. Age and body weight were found to have no effect upon the 3 
conjugation pathways studied. Sex differences were found in the 
glycine conjugation of salicylate but not in the glucuronide and 
sulphate conjugations of paracetamol. The effects of oral contra­
ceptive steroid (OCS) use and smoking on the 3 conjugation pathways 
were also studied. Glycine conjugation of salicylate was not 
affected by either. Paracetamol glucuronidation was increased by 
OCS and smoking whereas paracetamol sulphation was found to be 
decreased only by OCS use.
The population studies for both aspirin and paracetamol showed that 
glycine, glucuronide and sulphate conjugation are not subject to 
genetic control.
2. The metabolism of estradiol was studied in OCS users and non­
users in order to examine the effects of the single environmental
factor, OCS, on endogenous metabolism. The plasma concentration of 
endogenous estradiol (E^ ) and the urinary excretion of its 
metabolites, free E^ , E^-glucuronide and E^-sulphate were all found 
to be decreased by OCS use. In addition, the metabolism of 
estradiol may be altered by OCS use; the results indicating that 
the oxidation of estradiol may be decreased and the 
glucuronidation may be increased.
3. A parallel study to 2. was performed in rats where female rats 
were chronically pretreated with ethinyl estradiol (EE^Jand the 
effects on paracetamol and estradiol metabolism were examined. 
Paracetamol glucuronidation was found to be induced by EE^ 
pretreatment whilst paracetamol sulphation was subject to a delayed 
decrease. Hence, it is proposed that EE^ may be the component of 
the combined OCS responsible for the increase in paracetamol 
glucuronidation found in females. Similarly, the urinary excretion 
of total estradiol was found to be‘increased by EE^ pretreatment 
although the small intestine content of estradiol was found to be 





Many drugs upon entering the body are transformed into other 
substances. The result of these processes is that the polarity of 
the compounds are increased so that they are readily excreted from 
the body in the urine and bile. Williams (1971) summarised the 
possible fate of drugs in the body as follows:
1. Drugs can undergo enzyme-catalysed transformations.
2. Drugs can be excreted unchanged (e.g. cyclamate; deca- 
methonium).
3. Drugs can undergo a spontaneous reaction when given the 
appropriate physical conditions, such as pH (e.g. 
thalidomide)
Most drugs fall into the first category and the enzymes responsible 
for the transformations are found mainly in the liver, and to a 
lesser extent in other tissues including the intestine, kidney and 
lung. The process of biotransformation or metabolism is regarded as 
occurring in 2 phases, and can be summarised as follows:
Phase I Metabolism
Phase I involves oxidation, reduction and/or hydrolysis and can 
result in
a) inactivation of the drug (e.g. oxidation of tolbutamide)
b) conversion of an inactive drug into an active metabolite 
(e.g. prontosil->sulphonilamide)
c) conversion of one active drug into another (e.g. phenacetin 
—^  paracetamol).
Phase I reactions usually introduce chemical groups such as -OH, 
-COOH or -NH^ which allow phase II metabolism or conjugation to 
occur. However, if a drug contains suitable groups, it can undergo 
phase II metabolism directly, as no phase I reaction is necessary.
A drug may undergo only phase I metabolism as in the case of 
ethanol, which is oxidised mainly to CO^. In general, phase I 
metabolism results in the polarity of the compound being increased, 
but the activity still remains.
Within phase I metabolism there are 3 major reactions, namely 
oxidation, reduction and hydrolysis and of these oxidation is the 
most common. All oxidation reactions require NADPH^ and 0^ and the 
enzymes responsible are usually found in the endoplasmic reticulum 
or microsomal fraction of the hepatic cell. Similarly, reduction 
involves hepatic microsomal enzymes whilst the enzymes responsible 
for hydrolysis are widely distributed throughout the body.
Phase II Metabolism
Phase II metabolism consists of synthetic reactions where the 
parent drug or its phase I metabolite is coupled with an endogenous 
substrate. Unlike phase I it generally results in termination of 
biological activity.
Within phase II metabolism there are 10 major reactions, 8 of which 
occur in man. These reactions involve the coupling of a compound 
containing a suitable chemical group (such as OH, NH^ COOH) 
with an endogenous molecule such as glycine or glucuronic acid.
This endogenous molecule or conjugating agent is usually derived 
from the body's carbohydrate or protein sources.
As conjugations are synthetic reactions the majority require a 
source of energy which is usually supplied by adenosine triphos­
phate (ATP). ATP is required to form an intermediate activated 
nucleotide which is then catalysed by the transferring enzyme into 
the conjugation product. The intermediate nucleotide can be derived 
from either the conjugating agent or the compound undergoing 
conjugation as shown below:
_ . . ENERGY _ . COMPOUND „Conjugating _______ ^  Conjugating agent  ^  Conjugated
agent Nucleotide + TRANSFERASE pr°duct
CONJUGATING
_ , ENERGY „ , AGENT „ .Compound ^  Compound ^  Conjugated
Nucleotide product
+ TRANSFERASE
Of the conjugation reactions that occur in man, glucuronic acid 
conjugation is the most widespread and it is the only phase II 
reaction to take place in the microsomal fraction of the liver. Of
the other major phase II reactions, glycine conjugation occurs in 
hepatic mitochondria whilst sulphation occurs in the kidney and the 
intestinal mucosa as well as the soluble fraction of the hepatic 
cell. Similarly, acetylation has a wide distribution throughout the 
body (including the liver, lung and spleen) whilst the majority of 
mercapturic acid synthesis occurs in the kidney.
Although foreign compounds such as drugs and some food substances 
undergo metabolism upon entering the body, the same metabolic 
pathways are used by a variety of endogenous compounds. These 
include bilirubin, bile salts and the steroid hormones; by 
metabolism they lose their biological activity and/or are excreted 
from the body.
1.2 FACTORS AFFECTING DRUG METABOLISM
Large variations in drug response and therapeutic outcome may be 
observed if the same dose of a drug is administered to different 
individuals. One major factor contributing to interindividual 
differences is a marked variation in the capacity to metabolise 
drugs, which in turn is due to variations in the nature and amounts 
of enzymes responsible for drug metabolism. These enzymes and their 
activities are controlled by a complex interplay of genetic and 
environmental factors. Fig. 1.1 (Vesell, 1982) shows the known or 
suspected host factors that may influence drug response in man. The 
multiplicity of interaction amongst host factors and the modulation 
of these host factors by genetic constitution is also depicted.
5.
FIGURE I .1
The multiplicity of factors that may 






































This circular design suggest the multiplicity of either well- 
established or suspected host factors that may influence dru 
response in man. A line joins all such factors in the oute 
circle to indicate their close interrelationship. Arrows 
from each factor in the outer circle are wavy to indicate 
that effects of each host factor on drug response may occur 
at multiple sites and through different processes that 
include drug absorption, distribution, metabolism, excretion, 
receptor action, and combinations thereof.
Vesell 1Q82




a) Genetic Control of Drug Metabolism
There are 2 types of genetic control of metabolic reactions in man. 
In one type, a frequency distribution histogram relating incidence 
to metabolic response shows a continuous (normal) distribution with 
wide differences between the 2 extremes. This is due to the meta­
bolic reaction being controlled by a number of genetic and environ­
mental factors, and so the control is polygenic and multifactorial. 
In the second type a discontinuity of metabolic response is 
obtained whereby the frequency distribution histogram gives a 
bimodal or trimodal distribution. This indicates monogenic control 
with different individual modes corresponding to different allele 
pairing (Ritchie et at,, 1980). It is this second group which 
complies with the definition of genetic polymorphism:
"Genetic polymorphism is a type of variation in which individuals 
with sharply distinct qualities co-exist as normal members of a 
population". (Ford, 1965).
The condition is also defined as "the occurrence together in the 
same habitat of 2 or more discontinuous forms or phases of a 
species in such proportions that the rarest of them cannot be 
maintained by recurrent mutation". (Ford, 1942).
Many drugs undergo extensive metabolism which terminates biological 
activity when given orally, which affects the bioavailability of 
the active drug and the response obtained. The major factor 
responsible for such metabolism is hepatic oxidation which has been
found to be under genetic control. A good example of polymorphic 
drug oxidation is observed with the antihypertensive drug 
debrisoquine.
Polymorphism of Oxidation
The optimal dose requirements of debrisoquine have shown marked 
interindividual differences and these have been found to be due to 
differences in ability to metabolise the drug (Angelo et 
at., 1975). Further studies, showing a daily dosage range of 10 to 
360 mg in 120 hypertensive subjects, have found a positive 
correlation between the hypotensive response to debrisoquine and 
the amount of unchanged drug excreted in the urine (Silas et at., 
1977).
The major metabolic pathway of debrisoquine, 4-hydroxylation, is 
under genetic control (Mahgoub et at., 1977). The metabolic ratio 
between the urinary excretion of the parent drug and its principal 
metabolite, 4-hydroxydebrisoquine, gave a bimodal distribution with 
2 distinct phenotypes of extensive and poor metabolisers. 
Approximately 7 - 9% of the U.K. population are poor metabolisers 
of debrisoquine although this frequency appears to be different in 
other ethnic groups (Kalow et at., 1982). Family studies have shown 
that this phenotype is controlled by an autosomal recessive gene 
(Mahgoub et at., 1977). The genotype responsible for deficient 
4-hydroxylation also controls a wide variety of phenotypes 
characterised by deficient metabolism of numerous drugs. These 
include sparteine, nortriptyline, phenytoin, guanoxan and 
phenacetin and certain P-blocking drugs such as metoprolol,
bufuralol and timolol. At least 22 drugs have been found to undergo 
the same hepatic drug oxidising pathway through which debrisoquine 
passes.
Polymorphism of Hydrolysis
The cytochrome P.,—  responsible for the oxidation of debrisoquine 
4oU
and other related compounds is not the only enzyme system in man to 
be under genetic control. Hydrolysis is also subject to poly­
morphism as seen with the muscle relaxant, succinylcholine. As the 
enzyme responsible for succinylcholine hydrolysis, pseudocholin- 
esterase, is found in the plasma and so is readily accessible, 
sin in vitro test is performed to determine the dibucaine number 
which represents the affinity of the enzyme for succinylcholine. A 
trimodal distribution of the dibucaine number is obtained smd the 
three phenotypes are due to the autosomal smd autonomous control of 
the hydrolytic enzyme. It is subjects who are homozygotes of the 
atypical pseudocholinesterase who are slow metabolisers of 
succinylcholine.
Polymorphism of Acetylation
Drugs which undergo N-acetylation, a phase II metabolic reaction, 
have also been found to show polymorphism. Both plasma isoniazid 
concentrations smd urinary excretion of unchanged isoniazid gave a 
bimodal distribution with the 2 phenotypes of rapid smd slow 
acetylation (Evans et at., 1960). Family studies have shown that 
the slow N-acetylator phenotype is an autosomal homozygous 
recessive. As with cytochrome P^q polymorphism a variety of drugs
which under N-acetylation also exhibit deficient metabolism in a 
percentage of the population. These include dapsone, hydralazine, 
procainamide, phenelzine, nitrazepam and certain sulphonamides such 
as sulfapyridine and sulfadimidine. Approximately 38% of British 
Caucasians are slow acetylators but this percentage varies widely 
between ethnic groups.
The Significance of Polymorphism of Oxidation, Hydrolysis and 
Acetylation
Metabolism, phase I and/or phase II is responsible for the 
inactivation of many drugs. Therefore variations in metabolism can
be a major influence on interindividual differences in responsive­
ness to drugs. This can be seen in the polymorphisms of oxidation, 
acetylation and hydrolysis where a drug's response is related to 
the phenotype of the subject;. For example, pooroxidisers , when 
administered debrisoquine, are more likely to develop postural 
hypotension than extensive oxidisers. Similarly, upon 
administration of isoniazid,slow acetylators are more susceptible 
to its toxic effects such as peripheral neuritis, whilst slow 
hydrolysers are more prone to prolonged apnoea than rapid hydro- 
lysers when given succinylcholine. Toxicity of pharmacogenetic 
origin occurs when subjects are given drugs which they are gene­
tically unable to inactivate in the usual way, resulting in drug 
accumulation. Thus pharmacogenetics deals with inborn errors of 
metabolism involving defective enzymes that convert pharmaco­
logically active drugs into inactive metabolites.
b) Environmental Control
The activity of drug metabolising enzymes can be altered by 
numerous environmental factors, although the majority of this 
research has concentrated on hepatic microsomal metabolism. A 
summary of the factors known to affect metabolism as stated by 
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Due to the large number of factors which have been proposed to 
affect drug metabolism, only those which are of particular 
relevance to the present work will be discussed further.
Other Drugs or Foreign Compounds
Chronic administration of one drug can result in decreased 
pharmacological activity of another drug by stimulating its 
inactivating metabolic pathway thus reducing its concentration at 
its active site(s). Such stimulation of metabolic enzymes is caused 
by the amount of enzyme being increased, which is the result of
either sin increase in enzyme synthesis or a decrease in enzyme 
degradation. Enzyme stimulation is known as enzyme induction and 
when compounds capable of enzyme induction are given concomitantly 
with another drug, the metabolism and therefore the activity of the 
second drug are altered. Examples of drugs which are capable of 
causing enzyme induction include polycyclic hydrocarbons such as 
3-methylcholanthrene and 3,4-benzpyrene which show considerable 
substrate specificity and barbiturates which are relatively 
non-specific. Conney and Burns (1962) have reviewed the enzyme 
induction of microsomal enzymes.
Age
The newborn are known to have a reduced capacity for drug 
metabolism, with the most prominent effect being in reduced 
glucuronyl transferase activity. This results in a reduced ability 
to conjugate bilirubin and transient hyperbilirubinaemia may occur. 
However, as the baby grows, the capacity for glucuronide 
conjugation increases.
There is now increasing evidence to show that drug metabolism is 
impaired in old age. The elderly have been found to have 
significantly reduced plasma clearance of several drugs including 
antipyrine, chlormethiazole, phenylbutazone and quinine, all of 
which undergo oxidation. For a review on metabolism and the 
elderly, see Crooks and Stevenson, 1977. Conjugation pathways 
including glycine, glucuronide and sulphate conjugation also appear 
to be affected by age. The plasma clearance of drugs which undergo 
phase II metabolism, such as aspirin and paracetamol, have also
been found to be 'significantly reduced in the elderly (Ho et at,, 
1985; Triggs et at., 1975 respectively).
Sex
Sex differences in drug metabolism have mainly been studied in rats 
sind some phase I metabolic pathways have been found to be sex- 
dependent whilst others are relatively independent of sex (Kato, 
1974). Similarly, recent studies have determined the effect of sex 
on oxidative drug metabolism in man with drugs such as eintipyrine 
(Teunissen et at,, 1982), diazepam (Greenblatt et at., 1980) and 
chlordiazepoxide (Roberts et at., 1979) showing sex differences.
Disease and Diet
Changes in nutritional states and numerous pathological states such 
as liver and kidney disease, hormonal disturbances, tumour-bearing 
states and adjuvant arthritis are all capable of affecting hepatic 
metabolism. Phase I microsomal metabolic pathways are generally 
more susceptible to such changes in nutritional and pathological 
states but other pathways such as conjugation can be affected to a 
lesser extent. Kato (1977) provides an excellent review of the 
effects of disease and diet on drug metabolism.
In the present work, the metabolism of aspirin and paracetamol was 
studied in human volunteers in order to identify the environmental 
factors that may affect the major metabolic pathways of these 2
commonly-used compounds. These 2 studies were also performed to 
show whether the major metabolites of paracetamol and aspirin are 
subject to genetic control. A further study was performed in order 
to assess the effect of a single environmental factor; chronic use 
of oral contraceptive steroids, on endogenous estradiol metabolism 
in female volunteers.
1.3 ASPIRIN
The salicylates have been used for over 2000 years in the treatment 
of a variety of conditions. Salicylin was first isolated from 
willow bark in 1826 but it was not until 1893 that Felix Hoffman 
developed a commercial method for synthesising aspirin, thus 
bringing it into widespread use. Today the salicylates are 
available in hundreds of different forms and annual world 
consumption can be measured in billions of doses.
a) Mode of Action and Therapeutic Uses
Analgesic Effect
Salicylates are mild analgesics which are effective in relieving 
mild to moderate pain. Lim (1964) demonstrated that aspirin acts 
peripherally as opposed to morphine which has a central action. 
Salicylates are believed to cause pain relief by inhibiting the 
local synthesis and release of prostaglandins (Ferreira and Vane, 
1974). They are not effective as analgesics in non-inflamed tissues 
where prostaglandins are not responsible for the pain. Thus, 
salicylates are effective in the dull throbbing pain of inflam­
mation where prostaglandins apparently sensitise the nerve endings 
but are ineffective in sharp, stabbing pain caused by direct 
stimulation of the nerves.
Salicylates are an effective analgesic for pain of moderate 
intensity such as headache, myalgia, arthralgia, and dysmenorrhea. 
They are also particularly effective at controlling chronic 
post-operative pain or pain arising from inflammation.
Anti-inflammatory Effect
Salicylates modify or diminish the inflammation process, but are 
not capable of arresting it. Numerous mediators are known to be 
involved in inflammation including histamine, 5-hydroxytryptamine, 
slow releasing substance of anaphylaxis, bradykinin and prosta­
glandins. Salicylates exert their antinflammatory effect by 
inhibiting the synthesis and release of bradykinin and prosta­
glandins (Barnett et at,, 1982). The Anti-inflammatory effects of 
salicylates are used in the treatment of musculoskeletal disorders 
such as rheumatoid arthritis, osteoarthritis and alkylosing 
spondylitis. However, they only provide symptomatic relief; the 
progression of the disease is not arrested.
Antipyretic Effect
During inflammation, endogenous pyrogen is released which causes 
prostaglandin to be released from discrete sites within the 
brain, resulting in an elevation of body temperature. Salicylates 
are effective antipyretics as they inhibit prostaglandin production 
so preventing further increases in body temperature.
Antithrombotic Effect
Aspirin reduces platelet aggregation. Thromboxane A^ induces 
platelet aggregation and prostaglandin Iinhibits platelet 
aggregation. If a suitably low dose of aspirin is given, selective 
inhibition of thromboxane A^ occurs, resulting in decreased 
platelet aggregation.
Aspirin has been suggested as an antithrombotic agent to be used in
thrombotic diseases such as coronary artery disease, myocardial 
infarction and post-operative deep vein thrombosis. However, much 
controversy still exists regarding the efficacy of aspirin in this 
area.
b) Toxicity
The most common adverse effects of salicylates are associated with 
the gastrointestinal tract (Silvoso et at,, 1979) namely irritation 
of the gastric mucosa, which at high doses can result in exacer­
bation of peptic ulcer, dyspepsia, gastric bleeding and erosive 
gastritis. Salicylate induced gastric bleeding is painless and 
although it frequently leads to blood loss in the stools, iron- 
deficiency anaemia occurs only occasionally.
Central nervous system toxicity is also found with salicylates. 
Tinnitus, deafness, headache, and dizziness often occur at high 
doses but disappear on reduction of the dose.
High doses of aspirin have been associated with nephrotoxicity. 
Transient shedding of renal tubular cells, alteration in urate 
clearance and reversible renal functional impairment have been 
found. However, severe renal failure is most rare, although 
nephrotoxicity is associated with prolonged use. Similarly, high 
doses of salicylates may be capable of causing liver damage. The 
hepatic damage takes up to several weeks to occur and results in 
elevated levels of plasma transferases.
Aspirin allergy is found in approximately 1% of the population and 
symptoms include urticaria-angiodema, bronchospasm, severe rhinitis
or shock. This hypersensitivity is more common in asthmatics or 
other individuals with allergies but the aspirin allergy is not 
thought to be an immunological reaction.
1.4 METABOLISM OF ASPIRIN
Absorption and Distribution
Upon oral administration, aspirin is rapidly absorbed from the 
stomach and more extensively from the jejenum (due to the large 
surface area). The absorption occurs by a passive diffusion of 
non-ionised, lipophilic molecules (aspirin and salicylic acid) 
across the gastro-intestinal membrane.
Approximately 60% of the aspirin dose reaches the systemic 
circulation intact (Rowland et at,, 1972). The remaining dose 
undergoes first-pass hydrolysis by. esterases found in the intestinal 
wall, liver and plasma. A peak plasma concentration of aspirin is 
obtained within approximately 25 minutes for soluble aspirin 
preparations (Rowland et al. 3 1972) but it declines rapidly as it 
is hydrolysed to salicylic acid.
Aspirin (ASA) and salicylic acid (SA) are both partially bound to 
serum proteins with SA being more extensively bound than ASA. 
However, the protein binding of both ASA and SA differs from other 
drugs in that it is dose-dependent; the fraction of the dose bound 
decreases as the serum concentration increases (Paulus et at. s 
1971). They are both distributed throughout most body fluids and 
have been detected in spinal, synovial and peritoneal fluids, 
saliva and breast milk.
FIGURE 1.2
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Aspirin is rapidly converted to salicylic acid by esterases found 
in the plasma, liver and intestinal wall. The majority of salicylic 
acid undergoes further metabolism but some is excreted unchanged. 
Salicylic acid (SA) undergoes conjugation with glycine to form the 
major metabolite, salicyluric acid (SUA). It is also conjugated 
with glucuronic acid to form phenolic (SPG) and ester or aryl (SAG) 
glucuronides. Ring hydroxylation of SA forms the minor metabolite, 
gentisic acid (GA). Further metabolites of SA have also been found, 
namely the phenolic glucuronide of salicyluric acid (SUA-PG) and 
the glycine conjugate of gentisic acid, gentisuric acid (GUA). Free 
SA and its metabolites are eliminated from the body by the kidney. 
The metabolites are subject to glomerular filtration but free SA is 
also actively secreted by the proximal tubule.
Pharmacokinetics
Following a therapeutic dose of 650 mg ASA, the plasma half-life 
of ASA is 15 minutes whereas the half-life of SA is 4 hours (see 
Needs and Brooks, 1985, for a review on aspirin pharmacokinetics 
and metabolism). Therefore, SA is distributed in and eliminated 
from the body more slowly than ASA. At low doses of aspirin of less 
than 300 mg, the overall elimination of salicylate is described by 
first-order kinetics (Bedford et at., 1965; Levy, 1965). However, 
at higher, therapeutic doses some of the metabolic processes become 
capacity-limited as salicylate levels increase, whereas the 
formation of the minor metabolites, GA, SAG and the excretion of 
unchanged SA remain first-order (Levy et at., 1972). At the
therapeutic dose of 600 mg of ASA, the maximum rate of SUA 
formation is approached but the formation of SPG remains a 
first-order process (i.e. linear). The usual therapeutic dose of 
ASA is 600 mg every 6 hours giving free SA plasma concentrations of 
less than 60jig/ml and a plasma half-life of 4 to 6 hours. In 
arthritis, free SA plasma concentrations of 200 to 350 jug/ml may 
be required, and plasma half-life may be prolonged to 15 hours or 
more.
1.5 PARACETAMOL
Acetanilide was first introduced into medicine in 1886, as an 
effective antipyretic. However, it was found to cause cyanosis and 
so less toxic alternatives were sought. Baron von Mering discovered 
phenacetin and paracetamol, both of which are derived from acet­
anilide and are just as effective but less toxic. Von Mering 
thought paracetamol was too toxic and so phenacetin came to replace 
acetanilide. Howevdr, as phenacetin was found to cause severe renal 
necrosis, the use of paracetamol increased and in 1949, when 
paracetamol was recognised as the major active metabolite of both 
acetanilide and phenacetin, it became very popular. It is now 
widely used for many minor painful and febrile conditions.
a) Mode of Action and Therapeutic Uses
Analgesic Effect
The analgesic effects of aspirin and paracetamol are comparable as 
they are both effective in relieving pain of moderate intensity. As 
with aspirin, the analgesic effect of paracetamol is due to 
inhibition of prostaglandin synthesis. However, paracetamol is 
approximately 10 times less effective than aspirin as an inhibitor 
of peripheral prostaglandin synthetase, but it has the same potency 
on the prostaglandin synthetase in the brain (Ferreira and Vane, 
1974). As paracetamol only has a weak anti-inflammatory action but 
is an effective analgesic it should be used in relieving mild to 
moderate pain which is not accompanied by significant inflammation, 
such as headache, myalgia, arthralgia and dysmenorrhea.
Antipyretic Effect
Paracetamol is effective in lowering an elevated body temperature. 
As with aspirin it prevents the synthesis and release of 
prostaglandins in the brain caused by endogenous pyrogens.
b) Toxicity
High doses of paracetamol have occasionally been found to cause 
destruction of erythrocytes, resulting in haemolytic anaemia. In 
some instances this is due to glucose-6-phosphate dehydrogenase 
deficiency in the red blood cell but it caui also be due to 
paracetamol metabolites oxidising haemoglobin and glutathione and 
SH groups in the wall of the erythrocyte.
Paracetamol has been associated with nephrotoxicity, but due to the 
very large doses that have to be taken, paracetamol induced kidney 
damage is very rare (Prescott, 1982), although it does occur in the 
overdose patient.
Liver damage is the major toxic effect of paracetamol although it 
only occurs at high doses. It is usually associated with acute 
toxicity as in an overdose but there are a few instances where 
chronic paracetamol use has resulted in liver damage. As little as 
5 g of paracetamol in a single dose can cause acute hepatic 
necrosis and 15 g can result in death. Liver injury is usually 
evident as elevation in serum bilirubin, transaminase and lactate 
dehydrogenase concentrations and prolonged prothrombin time. 
However, if the paracetamol toxicity is treated and it proves
non-fatal, the hepatic necrosis is slowly reversible over the 
following months.
1.6 METABOLISM OF PARACETAMOL
Absorption and Distribution
Paracetamol is rapidly absorbed from the gastrointestinal tract and 
peak plasma concentrations occur 30 to 60 minutes after ingestion 
(Heading et at., 1973). Paracetamol is also subject to dose- 
dependent first-pass metabolism. As the dose of paracetamol 
increases, the proportion undergoing first-pass metabolism dec­
reases, to around 12% at a dose of 1 g or greater (Mucklow et at., 
1980). The majority of the pre-systemic metabolism occurs in the 
liver although a small amount of paracetamol conjugation does take 
place in the gastro-intestinal tract (Rogers et at., 1985, 1986).
Paracetamol is distributed throughout most body fluids. At thera­
peutic concentrations of 60ug/ml, paracetamol shows no plasma 
protein binding, but at toxic concentrations of 280yg/ml, 15 - 21% 
of paracetamol is protein-bound (Gazzard et at,, 1973).
Metabolism
The major metabolites of paracetamol (P) are the glucuronic acid 
and sulphate conjugates; paracetamol glucuronide (PG) and 
paracetamol sulphate (PS). Paracetamol is also subject to oxidation 
by cytochrome P-Crt which results in the formation of a reactive 
intermediate. At normal therapeutic doses, this intermediate is
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inactivated by further conjugation with glutathione. The 
glutathione conjugate is then further metabolised into paracetamol 
cysteine and paracetamol mercapturic acid.
Upon administration of greater doses, the larger amounts of the 
reactive intermediate may utilise all of the available supplies of 
glutathione. Therefore any excess metabolite is free to combine 
with cell constituents so causing liver damage.
The metabolites of paracetamol are mainly eliminated by the kidneys 
together with a small percentage of the unchanged parent compound.
Pharmacokinetics
Paracetamol elimination is a first-order process and it has a 
plasma half-life of approximately 2.5 hours (Nelson and Morioka, 
1963; Rawlins et at,, 1977). The therapeutic dose of paracetamol is 
0.5 to 1 g every 3 to 4 hours.
1.7 ORAL CONTRACEPTIVE STEROIDS
Oral contraceptive steroids (OCS) have been widely used for about 
20 years and are taken by approximately 60 million women throughout 
the world. The most common formulation for oral contraception is 
the combined preparation which contains 30 to 50 y g of an estrogen 
(usually ethinyl estradiol) and less than 1 mg of progestogen. The 
combined pill is usually administered for 21 days then stopped for 
7 days during which withdrawal bleeding occurs.
a) Mode of Action
The combined pill has several major sites of action including the 
hypothalamus and pituitary gland, the endometrium, the cervix and 
the Fallopian tubes.
Pituitary-hypothalamic factors
The progestogen content of the combined pill suppresses luteinizing 
hormone (LH) secretion by a negative feedback on the hypothalamus 
whilst the estrogen content suppresses follicle stimulating hormone 
(FSH) secretion in a similar fashion. Thus the combined pill 
maintains FSH and LH concentrations at normal luteal phase levels 
which results in the inhibition of ovulation. The lack of a 
follicular rise in FSH levels prevents the initiation of follicular 
development whilst the absence of an LH-FSH ovulatory surge 
prevents ovulation. Due to the suppressed LH and FSH levels and the 
inhibition of follicle development, endogenous estradiol 
concentrations in the blood remain low.
Endometrial factors
During oral contraceptive use, the endometrium is altered so that 
it is not receptive to ovum implantation. The progestogen component 
is mainly responsible for these changes whereby the endometrium 
regresses from a proliferative phase to a progestational phase 
which after several cycles of oral contraception can result in a 
decidualized bed with exhausted and atrophied glands. Although the 
endometrium is not a site for contraceptive action of the 
estrogenic component of the pill, it is responsible for increasing 
the stability of the altered endometrium, so preventing 
breakthrough bleeding from occurring.
Cervical factors
The progestogen component has a further contraceptive effect on the 
cervical mucus resulting in hindered sperm movement. It remains 
thick as in the normal luteal phase and is impervious to sperm 
transport.
Fallopian tube factors
The motility of Fallopian tubes and hence ovum movement is altered 
by the progestogen component of the combined pill, which may be a 
further contraceptive effect.
b) Toxicity
The combined oral contraceptive steroids (OCS) have been associated 
with many metabolic and systemic effects. A review of the side 
effects of OCS is given by Odell and Molitch, 1974.
Thromboemboli sm
One of the undesired effects that is associated with oral 
contraceptive steroids is the increased risk of deep venous 
thrombosis. OCS have been found to increase the relative risk of 
thromboembolism by a factor of 11 (Boston Collaborative Drug 
Surveillance Program, 1973). Further documentation links the 
increased risk of thrombosis with the dose of estrogen - as a 
result of which the dose of ethinyl estradiol present in the pill 
has been reduced from 100 jjg or more/day to 30 - 35 jig/day.
However, even at the lower doses of ethinyl estradiol, the 
increased risk of thrombosis is still present as confirmed by 
Stolley et at., 1975.
The mechanism by which oral contraceptives cause vascular 
complications is not known with certainty, however it is known that 
OCS alter blood coagulability. Oral contraceptive use has been 
found to elevate plasma levels of fibrinogen and factors VII and X 
whereas antithrombin III levels were found to decrease (Dugdale 
et at., 1971; Meade et at., 1976). All of these changes favour 
thrombosis but they sire largely offset by an increase in fibrino­
lytic activity.
Hypertension
There is a small risk of developing hypertension or exacerbating 
existing hypertension whilst using OCS (Weir et at., 1971 and 
Karagh et at., 1967). The estrogenic component is responsible for 
the increased incidence of hypertension and it is thought to 
activate the renin-angiotensin system. However, unlike
thromboembolism, the relative risk of hypertension is not decreased 
with a decrease in the dose of estrogen.
Carcinogenicity
Steroid contraception has been feared to cause cervical and breast 
cancer. However, there is no evidence to date to indicate that OCS 
increase the incidence of cancer. In fact, OCS have been found to 
have a protective effect towards benign breast tumours (Royal 
College of General Practitioners, 1974).
Glucose Tolerance
Glucose tolerance is impaired in 15 to 40% of OCS users and it is 
associated with elevated plasma concentrations of insulin and blood 
sugar. This effect is caused by an increase in peripheral resis­
tance to insulin action but its clinical significance is uncertain.
Lipid Metabolism
Oral contraceptives have been found to increase serum 
triglycerides, phospholipids and cholesterol concentrations, with 
the estrogenic component being responsible for the elevation of the 
first two only (Wynn et at., 1966; Stokes and Wynn, 1971). As 
elevated serum lipid and lipoprotein concentrations are associated 
with atherosclerosis, OCS may accelerate atherosclerosis in 
susceptible women, i.e. with either a family history or elevated 
serum lipids.
30.
1.8 METABOLISM OF ENDOGENOUS ESTRADIOL
There are 3 naturally occurring estrogenic hormones, namely 
estradiol (E )^, estrone (E^ ) and estriol (Eg)- Of these estradiol 
is the most potent and estriol has the weakest activity. The 
structures of these hormones are given below.






Upon administration of exogenous estradiol, 50 to 80% of the dose 
is excreted in the urine within 4 to 6 days, mainly as glucuronide 
conjugates and up to 20% is recovered in the faeces (Sandberg & 
Slaunwhite, 1957; Beer and Gallagher, 1955).
Phase I metabolism of estradiol
Estradiol is converted into estrone by 170 hydroxysteroid-
dehydrogenase and it is estrone which appears to be the precursor
of other estrogen metabolites. Estrone can then undergo further
oxidation at C-16 by cytochrome P.-- to form estriol.
4bU
Hydroxylation of estrogens can occur at C-2, C-4, C-6, C-7, C-ll, 
C-14, C-15, C-16 sind C-18 but the 2 major pathways involve C-2 and 
C-16. Hydroxylation at C-16 produces estriol whilst hydroxylation 
at C-2 (and C-4) produces the catechol estrogens. 2-hydroxylation 
and 160-hydroxylation are competitive in nature as an increase in 
16 0 -hydroxylase activity (as caused by an increase in body weight
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or cirrhosis of the liver or lowered level of thyroid hormones) 
results in a decrease in 2-hydroxylation (Fotherby, 1984).
Phase II metabolism of estradiol
Glucuronidation and sulfation are the major conjugation pathways of 
estrogens and formation of these metabolites usually results in 
rapid excretion from the body via urine or bile. Glucuronidation 
has been found to favour particular sites of the estrogen molecule, 
namely C-3 and the D-ring and as such estriol glucuronides are the 
major urinary metabolites of the estrogens but glucuronidation of 
estradiol and estrone also occurs. Formation of estriol glucuron­
ides occurs mainly in the liver, whereas estradiol and estrone 
glucuronides are thought to be formed at extrahepatic sites such as 
the kidney and the intestine (Hobkirk and Nilsen, 1974). 
Glucuronidation appears to be the major form in which estrogens are 
excreted in the urine but sulphation of the estrogens also occurs. 
Of these, estrone 3 sulphate is the most important, as this has 
been found to be the major circulating estrogen, with its plasma 
concentration exceeding that of estradiol about 10-fold (Longcope 
& Williams, 1974). Estrone 3 sulfate is rapidly formed from estrone 
in the liver and it is reconverted to estrone and estradiol by 
sulfatases and 17-P-hydroxysteroid dehydrogenase found in the liver 
and also in target tissues such as the uterus. Estrone 3 sulfate is 
regarded as a storage form of estradiol/estrone being in 
equilibrium with the free and active estrogens (Fotherby, 1984). 
Sulfation of estrone and estradiol occurs primarily in the liver 
but it may also occur at extrahepatic sites such as the intestine.
Double conjugates of estrogens have also been reported where 
glucuronide and sulphate conjugation occurs at 2 separate hydroxyl 
groups.
Catechol estrogens can be excreted in the urine unchanged but the 
majority undergo further transformation. The most important 
metabolic reaction for these estrogens is methylation catalysed by 
catechol-O-methyl transferase. The methoxy catechol estrogens 
produced by methylation then undergo further conjugation with 
glucuronide or sulphate prior to urinary excretion. A small 
percentage of the catechol estrogens are oxidised into the 
semiquinone form prior to either glutathione conjugation and 
urinary excretion or covalent binding to the -SH group of proteins.
Enterohepatic circulation
As well as the tramsformation of estrogens and/or their conjugation 
emd excretion into the urine, these steroids are also further 
inactivated by biliary excretion. Following exogenous admini­
stration of estradiol, 1 to 18% of the dose appeairs in the faeces 
whilst approximately 50% of the dose is excreted in bile, thus 
indicating that re-absorption of the estrogens has occurred 
(Sandberg and Slaunwhite, 1957).
Estradiol is excreted into the bile mainly as the glucuronide, 
estrone mainly as the sulphate and estriol mainly as the double 
conjugate. These conjugates are then hydrolysed in the intestinal 
tract and largely reabsorbed in the unconjugated form although some 
glucuronidation or sulphation may occur in the mucosal cells during 
absorption (Adlercreutz, 1970).
This circulation of estrogens results in their excretion from the 
body being delayed. However, as the reabsorption from the intestine 
is not complete, up to 20% of estrogens are excreted in the faeces.
Protein binding
Estradiol, estrone and estrone sulphate all bind to plasma 
proteins. Estradiol binds to albumin and the sex hormone binding 
globulin (SHBG) whereas estrone and estrone sulphate bind to 
albumin alone (Westphal, 1971).
1.9 METABOLISM OF ETHINYL ESTRADIOL
Natural estrogens are relatively inactive when given orally in 
comparison to synthetic estrogens. For example, whereas 30 - 50 jjg 
of ethinyl estradiol is administered per day in OCS, 4 mg of 
estradiol would have to be administered to achieve a comparable 
effect. This is probably due to the rapid clearance of endogenous 
hormones from the blood and an extensive first-pass effect.
However, in order for synthetic estrogens to gain estrogenic 
properties, they share structural properties with the natural 
endogenous estrogens and therefore they may be metabolised by the 
same enzymes which metabolise the natural estrogens. As ethinyl 
estradiol (EE^ ) is orally active, it has a slower elimination from 
the circulation if compared to estradiol. Like estradiol, urinary 
excretion of mainly glucuronide conjugates occurs, together with 
extensive metabolism at the steroid nucleus. Also, similar amounts 
of estradiol and ethinyl estradiol are excreted in the bile.
However unlike estradiol, ethinyl estradiol metabolites do not 
leave the body mainly via the urine. Urinary recovery is much lower 
than that of estradiol, whilst faecal recovery is much increased, 
resulting in a urine/faecal ratio of about 6 : 4 for ethinyl 
estradiol compared to the ratio of 8 : 2 for estradiol.
Phase I metabolism
As with the natural estrogens, the major pathway for ethinyl 
estradiol is aromatic hydroxylation with 2-hydroxy ethinylestradiol 
being the major metabolite (accounting for 29 to 64% of the dose) 
although 4-hydroxylation may occur. Further hydroxylation of EE^ at 
C-16 and C-6 have also been found.
Unlike estradiol, no hydroxylation at C-16 occurs which leads to 
the formation of estriol. This is mainly due to estrone being the 
substrate for estrogen 16p~hydroxylase and the introduction of the 
ethinyl group at C-17 prevents the estrone analogue from being 
formed. The lack of 16 Phydroxylation and subsequent estriol 
formation is thought to be the reason for the slower breakdown of 
ethinyl estradiol.
De-ethlnylatioir of ethinyl estradiol has been found resulting in the 
formation of estradiol and estrone although controversy exists 
concerning the quantitative extent. 15 to 20% of the total glucu- 
ronide metabolites of EE^ in urine were found to be de- ethylated, 
whereas only 1 - 2% of mestranol was found to undergo de-ethyl- 
ation, even though 50% of mestranol is converted into EE^. 
D-homoannulation is a minor metabolic pathway of ethinyl estradiol 
that is not found in estradiol metabolism. It involves enlargement
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conjugation -SH of proteins
of the D ring and oxidative elimination of sin ethinyl carbon atom.
Phase II metabolism
Ethinylestradiol cam be directly conjugated to form 
EE^-S-glucuronide and EE^-S-sulfate. The glucuronide conjugate is 
excreted in the urine but it is also subject to enterohepatic 
circulation. The sulfate conjugate is the principal circulating 
form of EE^ with its plasma levels approximately 10 times higher 
than those of EE^. Therefore it is considered to play the same role 
as estrone-3-sulfate whereby it represents a plasma transport and 
storage form of EE^ from which hydrolytic enzymes may release free 
and active EE^.
The products of aromatic hydroxylation of EE^ (2-hydroxy and 
4-hydroxy ethinyl estradiol) undergo the same metabolic pathways as 
utilised by the catechol estrogens as discussed in 1.8. That is, 
they are subject to conjugation with glutathione, covalent binding 
to proteins and methylation with catechol-O-methyl transferase. The 
major urinary metabolite of EE^ is 2-methoxy EE^ which is excreted 
as the sulfate or the glucuronide conjugate (see Helton & 
Goldzieher, 1977 and Ranney, 1977, for reviewson ethinyl estradiol 
metabolism and pharmacokinetics).
Pharmacokinetics of ethinyl estradiol
Ethinyl estradiol is rapidly and completely absorbed from the 
intestine but large interindividual variations in the plasma levels 
and the pharmacokinetics of EE^ have been reported.
Plasma levels of EE^ are known to decline bi-exponentially with the
initial decline having a half-life of about 1 hour whilst the 
second decline has a half-life of 7 to 8 hours (Warren and 
Fotherby, 1973). However, Back et at., (1979) described the 
occurrence of a secondary plasma peak at around 12 hours following 
the oral administration of 50 jug EE^, 'with a bi-exponential decline 
before this time point. This delayed secondary peak is indicative 
of extensive enterohepatic circulation of EE^ , as found with 
estradiol. The terminal decline has been found to have a half-life 
of 9.5 to 18.5 hours (Back et at. , 1980).
The pharmacokinetics of ethinyl estradiol have been found to vary 
greatly between ethnic groups. Nigerian women have a shorter half- 
life of EE^ than South and South-East Asian women, with American 
women having the longest half-life of all 3 groups (Helton and 
Goldzieher, 1977; Williams et at., 1980). Differences in metabolism 
between these races have also been found. Nigerian women demons­
trated relatively little oxidation and diglucuronides predominated 
in the urine whilst American womeii demonstrated a high degree of 
oxidation and monoglucuronides predominated, with South Asian women 
holding an intermediate position in oxidation and glucuronidation 
(Williams and Goldzieher, 1980).
1.10 SCOPE OF THE THESIS
Genetic and environmental control of phase I metabolism has been 
extensively studied. However, until recently little was known 
about the effects of these factors on phase II metabolism. 
Therefore, the effects of both genetic and environmental factors on 
phase II metabolism were examined in the present work, as phase II 
metabolism is generally responsible for the inactivation of a 
compound (exogenous and endogenous) NOT phase I metabolism, as 
shown in Figure 1.6. Aspirin and paracetamol are both commonly used 
drugs which are mainly inactivated by phase II metabolism and so 
they are suitable probe drugs to investigate genetic and/or 
environmental control of conjugation.
There ar’e wide interindividual variations in the plasma 
concentrations of aspirin and paracetamol, when a standard thera­
peutic dose is given to subjects for the control of pain in 
conditions such as rheumatoid arthritis. Such variation indicates 
that one or more factors are affecting the concentrations of 
salicylic acid or paracetamol. One major factor responsible for the 
concentration of a drug is drug metabolism, and interindividual 
variations in the metabolism of aspirin and paracetamol have been 
reported.
The population studies of aspirin and paracetamol, using healthy 
volunteers of a wide age-range, were undertaken to determine the 
factor(s) (both genetic and environmental) responsible for the 
variation in metabolism.
The population studies of aspirin and paracetamol can also 
determine the effects of the environmental factor, the use of oral
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contraceptive steroids (OCS), on the glycine, glucuronide and 
sulphate conjugation of these exogenous, foreign compounds.
However, little is known about the effect of OCS on endogenous 
metabolism. Therefore a population study was performed in healthy 
female volunteers to determine the effects of chronic OCS use on 
the metabolism of the endogenous hormone estradiol. As with the 
exogenous compounds, the effect on the major phase II metabolic 
reactions; glucuronide and sulphate conjugation were studied.
Figure 1.7 depicts the factors investigated in the human studies 
performed in this work.
Rat studies were also performed to determine the effect of chronic 
ethinyl estradiol administration, the usual estrogenic component of 
OCS, on the metabolism of the exogenous compound, paracetamol and 
the endogenous compound, estradiol. All 3 compounds are subject to 
glucuronide and sulphate conjugation and so this study can 
determine if there is any direct competition in the metabolism of 
these compounds. It can also determine if the estrogenic component 




Diagrammatic representation of the factors 
































i) soluble aspirin BP tablets, each tablet contained
300 mg. (Pharmacy, Royal United Hospital, Bath).
14ii) C-170 -estradiol - specific activity = 57.5 mCi/mmol 
(estra-l,3,5(lO)triene-3,170 -diol) MW = 272.4 (Du 
Pont Chemicals Ltd.)
iii) 170-ethinyl estradiol (170 ethinyl-l,3,5(10)estriene- 
3,170 diol) MW = 296.4 (Sigma Chemical Co.).
iv) hypnorm - Fentanyl citrate (0.315 mg/ml) + Fluanisone 
(10 mg/ml) (Janssen Veterinary Products Ltd.). 
midazolam hydrochloride (5 mg/ml) (Roche Products Ltd.) 
The anaesthetic was prepared by adding 1 ml of hypnorm 
to 2 ml of 0.9% saline followed by 1 ml of midazolam,
v) paracetamol B.P. tablets, each tablet contained 500 mg 
(Pharmacy, Royal United Hospital, Bath).
b) Analytes
i) o-anisic acid (o-methoxybenzoic acid) O-CH^OCgH^CO^H.
MW = 152.15 (Aldrich Chemical Co. Ltd.)
ii) gentisic acid (2,5-dihydroxybenzoic acid)-sodium salt 
(OH)^ CgHgCOONa, MW = 176.1 (Sigma Chemical Co.)
44.
iii) paracetamol B.P. (4-acetominophenol) CH^CONHCgH^OH
MW = 151 (Pharmacy, Royal United Hospital, Bath).
iv) paracetamol glucuronide (4-hydroxy N-phenyl acetamide
4-glucuronide) p-CHoC0NHC£;H>I0C^Hrt0^ , MW = 327 (kindly ® 3 6 4 6 9  6
donated by Stirling Winthrop, R & D).
v) paracetamol sulphate (4-hydroxy N phenylacetamide-
4-sulphate), p-CH^CONHC^H^OSO^H, MW = 230 (kindly 
o o 4 o
donated by Stirling Winthrop, R & D).
vi) salicylic acid (2-hydroxybenzoic acid)-sodium salt 
H0CeH COONa, MW = 160.1 (Sigma Chemical Co.)
O 4
vii) salicyluric acid (o-hydroxyhippuric acid)
H0C6H4C0NHCH2C02H, MW = 195.2 (Sigma Chemical Co.)
c) Solvents
i) acetone - analytical grade, CH COCH , MW = 58.08o o
(Fisons)
ii) acetonitrile (methyl cyanide) - HPLC grade.
CH3CN, MW = 41.05 (Fisons)
iii) chloroform - analytical grade, CHCl^, MW = 119.4 
(Fisons)
iv) isopropanol - HPLC grade, (CH^^CHOH, MW = 60.1 
(Sigma Chemical Co.)
d) Other Chemicals
i) formic acid, 98% HCOOH, MW = 46.03 (BDH Chemicals 
Ltd.)
ii) glucurase enzyme - (g -D-Glucuronide glucurono-
hydrolase from.bovine liver). Buffered at pH 5.0,
5000 units/ml (Sigma Chemical Co.)
iii) hydrochloric acid, HC1, MW = 36.46, SLR Grade
(Fisons)
iv) perchloric acid, 60% HCIO^, MW = 100.46 (Fisons)
v) potassium dihydrogen orthophosphate, KH^PO^,
MW = 136.09 (Fisons)
vi) orthophosphoric acid, 88%, H^PO^, MW = 98 (Fisons)
vii) saccharic acid 1,4 lactone, MW = 192.1 (Sigma 
Chemical Co.)
viii) sodium hydroxide, NaOH, MW = 40.0, AnalaR (BDH 
Chemicals)
ix) sulfatase enzyme (aryl sulfate sulfohydrolase from
helix pomatia - type H5) 19800 units/g with 
B-glucuronidase activity (Sigma Chemical Co.).
2.2 INSTRUMENTATION
a) High Performance Liquid Chromatography (HPLC)
Fig. 2.1 shows a generalised diagram of the HPLC system used. The 
mobile phase was pumped to the columns at a constant flow rate by a 
Laboratory Data Control (LDC) Constametric III Metering Pump (1) 
which provides a pulsation less flow using dual-reciprocating 
pistons. Samples were injected into the system using a rheodyne 
injection valve (2) fitted with a 20 pi 1 loop. Eluted compounds were 
detected on an LDC spectromonitor III Spectrophotometer (4) with a 
wavelength range in the UV- spectrum of 190 to 350 nm. (All of the
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above equipment was purchased from LDC, Stone, Staffs). 
Chromatographs were produced on a JJ Model CR550 potentiometric 
chart recorder (5) (JJ Lloyd Instruments Ltd.).
Both the 5 cm long precolumn (3a) and the 25 cm long analytical 
column (3b) consisted of stainless steel tubes with a 5 mm internal 
diameter, %" external diameter and were packed with reversed-phase 
microparticle silica, 5 Jim (Hypersil ODS, Shandon Products Ltd.). 
The column end fitting (female) consisted of a low dead-volume 
Swagelok connection with a 1/16" outlet which was connected to the 
detector by microbore Teflon tubing (internal diameter, 0.15 mm). 
Low dead-volume 1/16" stainless steel tubing (internal diameter, 
0.15 mm) was used to connect the injection valve to the top of the 
column. All other connections were made of stainless steel tubing 
and standard Swagelok fittings.
The equipment was operated at ambient temperature throughout.
Mobile phase was degassed by sparging with helium for 5 minutes 
prior to use.
b) Liquid Scintillation Counter
Radioactivity was measured in a LKB-Wallac Model 1215 Rack Beta 
Liquid Scintillation Counter. This automatic, microcomputer 
controlled four- channel scintillation counter is ideal for counting
beta emissions over the energy range 1 kev to 2800 kev. The samples 
were counted with external standard channels ratio method (ESCR).
2.3 HUMAN VOLUNTEERS
All human studies received approval from the Bath Health District 
Research Ethics Committee. All volunteers were judged healthy 
following an interview with a consultant physician and gave their 
informed consent.
For the aspirin and paracetamol studies, volunteers of both sexes 
aged between 18 and 65 years were recruited from the Pharmacology 
Group, University of Bath; the Royal United Hospital, and the 
Ministry of Defence sites, Foxhill and Ensleigh.
For the estradiol study, female volunteers aged between 18 and 35 
years were recruited from the Pharmacology Group and the Family 
Planning centres both at the University of Bath and at the Sawclose 
Family Planning Clinic, Bath. Two groups of young premenopausal 
women were recruited. One group had taken oral contraceptive 
steroids (OCS) for a minimum of 6 months whilst the second control 
group had never taken OCS. Details of oral contraceptive use and 
the day of the menstrual cycle on which the study was performed 
were recorded.
For all studies a record was made of the age and weight of the 
volunteers together with all drugs currently being taken.
2.4 ANIMALS
The experimental animals used were female Wistar rats (Bath 
University strain) weighing between 200 - 220 g.
Prior to collection of biological samples the rats were housed in 
groups of 10 per cage (NKP cages). Food pellets (Labsure diet CRM) 
and water were allowed ad libertum and a constant light-dark cycle 
was maintained (12 h light 7.00 to 19.00, 12 h dark 19.00 to 7.00) 
at an ambient temperature of 24°C.
To allow separate collection of urine and faeces the animals were 
placed in individual metabolism cages (NKP cages MCI) for 24 hours. 
Water was allowed ad libertum but food was restricted whilst urine 
was collected. Other conditions remained unaltered.
2.5 ADMINISTRATION OF DRUGS
a) To Humans
Each subject took soluble aspirin, 600 mg (2 x 300 mg tablets) in 
50 ml water or paracetamol, 1 g (2 x 0.5 g tablets) at 
approximately 8 am after voiding the bladder. All urine passed fron 
0 to 8 hours was collected in a urine container with no 
preservative.
For the estradiol study no drugs were administered. However, during 
a specific interval of the menstrual cycle a single 10 ml venous 
blood sample was obtained and urine was collected for 24 hours in a 
urine container with no preservative. For all studies urine Volume 
was recorded, together with urine pH for the aspirin study, and 2 x
10 ml aliquots taken. The blood was placed in heparinized tubes and 
then centrifuged at 3000 rpm for 15 min to obtain the plasma.
b) To Animals
For the paracetamol study the rats were treated orally for 40 days, 
between 9 and 11 am, with 1 ml of either 5% ethanol or ethinyl- 
estradiol in 5% ethanol (11 yg/ml), the 2 groups being randomly 
allocated. On day 29 of treatment each animal received a single 
oral dose of paracetamol (50 mg/kg) and was then placed in a 
metabolism cage and urine collected from 0 to 8 and 8 to 24 hours. 
On day 40 a second oral dose of paracetamol (50 mg/kg) was 
administered; the animals were anaesthetised with hypnorm and 
medazolam (0.1 ml/25 g) and then bled by cardiac puncture at 
intervals over 8 hours. Each animal was bled up to 4 times, with a 
maximum of 2 ml of blood taken at each bleed.
For the estradiol study the rats were again treated for 40 days as
above. On day 40 half of the rats were anaesthetised with hypnorm
and medazolam (0.1 ml/25 g) and the jugular vein and carotid artery
were cannulated. ^C-17Pestradiol (26.6 yg E^ ; 5.075 yCi/kg) was
administered through the jugular vein and blood was removed from
the carotid artery at intervals over 3 hours. Each animal was bled
up to 8 times with a maximum of 0.5 ml of blood taken at each
14bleeding. The remaining rats had C-estradiol (26.6 yg estradiol;
5.07 yCi/kg) injected iv into the tail vein on day 40 and were then 
placed in metabolism cages for a 24-hour urine and faeces coll­
ection. The animal was then sacrificed and the kidney, liver, small
and large intestine removed.
In both animal studies the blood was allowed to clot in serum tubes 
before being centrifuged at 3000 rpm for 15 minutes.
2.6 STORAGE OF BIOLOGICAL SAMPLES
All samples were stored at -20°C prior to analysis. Urine was 
stored in approximately 2 x 10 ml aliquots where possible. Serum 
samples were stored in unheparinized tubes, plasma samples in 
heparinized glass tubes.
2.7 ANALYSIS OF ASPIRIN METABOLITES
Salicylic acid (SA) and salicyluric acid (SUA) were assayed in 
human urine by HPLC. The method was a modification of that of Cham 
et at. (1980), using o-anisic acid as the internal standard.
HPLC Conditions
Mobile phase : 30% acetonitrile
70% orthophosphoric acid (0.1%)
pH =2-45
Flow rate : 1.5 ml/min
Detection : 298 nm
Chart speed : 0.4 cm/min
Assay Procedure
1 ml of urine was added to 1 ml of internal standard (o-anisic
acid, 0.5 mg/ml in distilled water). 100 pi was injected onto the
column
Analyte Retention Time max
salicyluric acid 3 min 55 sec 237, 297
o-anisic acid 4 min 47 sec 235, 292
salicylic acid 7 min 33 sec 230, 295
A typical chromatogram of SA and SUA in human urine following an 
oral dose of aspirin is given in Fig. 2.2.
The calibration curves for SA and SUA were found to be linear over 
the ranges 6 to 120 ug/ml and 50 to 1008 ng/ml respectively, as 
shown in Fig. 2.3.
2.8 ANALYSIS OF PARACETAMOL AND ITS MAJOR METABOLITES
a) In Urine
Paracetamol (P), paracetamol glucuronide (PG) and paracetamol 
sulphate (PS) were assayed in human and rat urine by HPLC. The 
method was a modification of that of Adriaenssens and Prescott 
(1978) using gentisic acid as the internal standard.
HPLC Conditions





Typical chromatogram for salicylic 

















0-2 0-6 0*8 1*0
r = 0.9997 





































1 ml of urine was added to 1 ml of internal standard (gentisic 
acid, 5.0 mg/ml in distilled water) and made up to 10 ml with 
distilled water. 100 nl was injected onto the column.
Analyte Retention Time X (nm)J max
Paracetamol glucuronide 3 min 47 sec 242
Paracetamol sulphate 6 min 12 sec 240
Paracetamol 8 min 15 sec 242
Gentisic acid 10 min 14 sec 243
A typical chromatogram of P, PG and PS in human urine following an 
oral dose of paracetamol is given in Fig. 2.4(a).
The calibration curves for P, PG and PS were found to be linear 
over the ranges 9.6 to 192.0 Mg/ml, 161 to 3220 Mg/ml and 74 to 
1482m g/ml respectively. Typical calibration curves for paracetamol 
metabolites in urine are shown in Fig. 2.5.
b) In Serum
Paracetamol in serum was assayed in rat serum by HPLC using the 
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0.5 ml of serum was added to 0.5 ml of internal standard (5.0 mg/ml
gentisic acid). A further 0.5 ml of perchloric acid (15%) was added
and after mixing, centrifuged at 3000 rpm for 15 minutes. 100 pi of
the supernatant was injected onto the column.
Analyte Retention Time * ( nm)max
Paracetamol 9 min 56 sec 242
Gentisic acid 13 min 17 sec 243
A typical chromatogram of paracetamol in rat serum following an 
oral dose of paracetamol is given in Fig. 2.4(b).
The calibration curves for paracetamol in serum were linear over 
the ranges 0.55 to 5.5 ug/ml and 3,15 to 63.0 ug/ml as shown in 
Fig. 2.6.
2.9 ANALYSIS OF 173-ESTRADIOL
a) In Plasma
170-estradiol was assayed in human plasma using an estradiol direct 
Radioimmunoassay (RIA) kit (purchased from Sorin Biomedica).
Assay Procedure
12550 pi of plasma sample was added to 100 pi of tracer ( 1-170
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the contents mixed with a vortex mixer. The tubes were incubated 
overnight at room temperature. The following morning, 1 ml of 
precipitating reagent obtained from the kit was added to each tube 
which was then mixed with a vortex and left to stand at room 
temperature for 15 minutes. The tubes were centrifuged at 4000 rpm 
for 20 minutes and the supernatant discarded by inversion. The 
radioactivity of the precipitate was finally measured using the 
gamma counter.
Kit Specificity
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b) In Urine
173-estradiol was analysed in human urine using the estradiol 
radioimmunoassay kit as for the plasma samples.
Assay Procedure
Prior to use of the kit, estradiol glucuronide and estradiol 
sulphate were enzymatically deconjugated. The concentration of 
these metabolites was determined by assaying total estradiol 
concentration before and after deconjugation.
A 5 ml aliquot of urine was taken and its pH altered to pH 5.0 
using 1.0 N hydrochloric acid. To 2 x 0.75 ml aliquots, 0.75 ml 
glucurase was added. To a further 2 x 0.75 ml aliquots 10 mg 
sulfatase was added and as this enzyme has glucuronidase activity 
0.75 ml of 0.02 M saccharate lactone (a glucuronidase inhibitor) 
was also added. The glucurase-treated, sulfatase-treated, and blank 
urine were left to incubate at 37° for 24 hours.
Following incubation each aliquot had its pH re-altered to pH 7.4 
(± 0.05) using 1 N sodium hydroxide and was then assayed for 
estradiol. The assay procedure for estradiol in urine was identical 
to that given in 2.9(a) with a 50 yl urine sample replacing the 
50 ]i 1 serum sample.
The calibration curve for estradiol was linear over the range 25 to 
500 pg/ml as shown in Fig. 2.7.
2.10 DETERMINATION OF RADIOACTIVITY IN BIOLOGICAL SAMPLES
Total radioactivity of urine and serum samples; kidney, liver,
63.
FIGURE 2.7
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small and large intestinal and faecal homogenates were measured 
using the LKB Wallac 1215 Liquid Scintillation Counter. All of 
these measurements were performed on the day the animal was 
sacrificed. The kidney, liver, small and large intestinal and 
faecal homogenates were prepared by homogenising the total tissue 
in N-saline (0.9% NaCl) using a Thyristor Regler TR50.
The following respective volumes of N-saline were added to the 
tissues prior to homogenisation: 10 ml; 20 ml; 20 ml; 30 ml; 10 - 
30 ml.
100 yl of the homogenate or urine/serum sample was added to 10 ml 
liquid scintillant, Optiphase. The vials were capped, mixed and 
counted for 120 seconds. Each sample was measured in duplicate.
2.11 QUANTITATION OF ASPIRIN METABOLITES, PARACETAMOL AND ITS 
METABOLITES AND ESTRADIOL IN BIOLOGICAL FLUIDS USING 
STANDARD CURVES
a) Preparation of Standard Curves
i) Aspirin and paracetamol metabolites
Five to eight urine or serum samples spiked with a range of solute 
concentrations plus a constant concentration of the respective 
internal standards were assayed in duplicate by HPLC. The peak 
heights for aspirin metabolites in urine and paracetamol and its 
metabolites in both urine and serum were determined together with 
the peak heights of the internal standards, and the peak height 
ratio calculated (i.e. peak height of the metabolite/peak height of 
the internal standard). Standard curves were checked throughout and
no significant variation was observed.
The data was fitted to the following equation using the linear 
least-squares regression method:
y = mx + c 
where y = peak height ratio
x = concentration of metabolite 
m and c = regression coefficients
ii) Estradiol
Seven urine or serum samples spiked with a range of estradiol 
concentrations were assayed in duplicate by radioimmunoassay. The 
net counts (totalCPM - background CPM) were determined for each of 
the standards and expressed as a percentage of the zero estradiol 
standard:
net count for standard (B) B
----------------------------    x 100 = |- %
mean net count for zero standard (B ) oo
Data was fitted to the following equation - the linear least- 
squares method:
y = mx + c
where y = B/B % o
x = Log^ (concentration of estradiol) 
m and c = regression coefficients
b) Linearity of Calibration Curves
From the calibration curve for each metabolite, the correlation 
coefficient r, the gradient, m and the intercept, c were calculated
using the linear least-squares regression method. For each 
calibration curve, every concentration point was obtained from an 
independent dilution.
c) Concentration Determination
Peak height ratios of the parent drug and/or its metabolites for 
aspirin and paracetamol were determined in serum and urine samples 
and concentrations were calculated using the equation:
x = y - c
m
where x = unknown concentration to be determined 
y = peak height ratio 
m and c = regression coefficients calculated from the 
calibration curves
The net count for total estradiol* in urine and serum samples was 
determined and concentrations were calculated using the equation:
Logio x ■ H r
where x = unknown concentration to be determined
y = B/B % o
m and c = regression coefficients calculated from the 
calibration curves 
All urine samples were diluted to ensure that they fell in the 
linear portion of the calibration curve.
2.12 STATISTICAL ANALYSIS AND TREATMENT OF DATA
Results were expressed as the mean ± standard.error of the mean. 
Further statistical analysis was performed using the computer 
statistical package, Minitab. Statistical difference was determined 
using either the student's t test (two-tailed, unpaired) or the 
Mann-Whitney test with statistical significance occurring at a 
probability of p < 0.05. For the t-test to be used 2 basic 
assumptions have to be fulfilled:
1) The distribution is not too markedly skewed, and
2) Population variances are equal, or
3) If population variances are unequal, then n^ + n^ > 60 and
ni s v
If these requirements were not satisfied then the Mann-Whitney test 
was used.
Probit plots were performed on all population distribution 
distribution data (Finney, 1971). A non-linear probit plot assumes 
deviation from a normal population. Deviation from linearity was 
determined by the x2-test, with statistical significance occurring 
at a probability of 0.05. A statistical significant x2 indicates a 
non-linear probit plot which in turn indicates deviation from a 
normal distribution.
The absolute quantitites of the paracetamol and aspirin metabolites 
in urine were expressed as the equivalent weight of paracetamol and 
salicylic acid respectively using the following conversion factors:
SUA (mg ) x 0.708 SUA as the equivalent weight of SA
PS(mg) x 0.657 PS as the equivalent weight of P
PG(mg) x 0.462 PG as the equivalent weight of P
(This treatment was not necessary for the estradiol data as
absolute quantities of estradiol metabolites were not determined).
CHAPTER THREE 
ASPIRIN METABOLISM IN HUMAN VOLUNTEERS
3.1 INTRODUCTION
Large interindividual differences in the serum concentration of 
salicylic acid (SA) and in salicylate excretion rates have been 
widely reported (including Caldwell et at., 1980; Levy and 
Hollister, 1964; Paulus et at. 3 1971; Gupta et at., 1975). Several 
studies have been performed in order to determine the cause(s) of 
this variation. Sex differences in salicylate metabolism have been 
found, however there is conflicting evidence concerning the effect 
of age on, and genetic control of, salicylate metabolism (Ho 
et at. s 1985; Oldham, 1983; Evans and Clarke, 1961; Furst et at., 
1977). By giving a therapeutic dose of aspirin to a large number of 
healthy adult volunteers and studying the excretion of salicylic 
acid and its major metabolite, salicyluric acid (SUA), the effect 
of both genetic and environmental factors on the glycine 
conjugation of salicylate was examined.
3.2 PROCEDURE
150 volunteers; 88 male, 62 female, were given aspirin (600 mg), 
which was taken in the morning after first voiding the bladder. 
Urine was collected for 0 - 8  hours and the urinary metabolites 
salicylic acid (SA) and salicyluric acid (SUA) were assayed by HPLC 
as described in 2.7. The quantity of SUA excreted is expressed as
the equivalent weight of SA, using the correction factor given in 
2.12.
The age range for males was 18 to 61 years with a mean (± SE) age
of 33.3 ± 1.5 years; the weight range was 60 to 102 kg with a mean
weight of 72.9 ± 1.0 kg. The age range for females was 18 to 59 
years with a mean age of 26.9 ± 1.4 years; the weight range was 44 
to 90 kg with a mean weight of 60.4 ± 1.2 kg.
The student's t test was used as the test for significance
throughout this study.
3.3 RESULTS
a) Environmental control of aspirin metabolism
Effect of urine pH
Urine pH has been well documented to affect salicylic acid 
excretion (Macpherson et al,, 1955; Gutman et at., 1955) and such 
an effect was found in this study. When total salicylate excreted 
in 8 hours was plotted against urine pH for the 150 subjects (Fig. 
3.1) a highly significant positive correlation was found (r =
0.732; p < 0.001). The best fitting curve describing this relation­
ship between urine pH and SA excretion was determined by computer 
analysis.
where x = urine pH
y = total SA excreted in 8 hr. 
a,b = regression coefficients
FTGPPF 1.L
Effect of urine pH on the 0.8 hr urinary excretion of SA.
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In order to determine the influence of other environmental and 
genetic factors on salicylate metabolism, the effect of pH had to 
be removed. This was done by correcting the total salicylate 
excretion at the pH observed, to a standardised pH of 6.2, the mean 
pH, using the method given below.
Correction Method
As the urine pH for each subject was known, the expected SA 
excretion for that pH was calculated using the formula:
where y = salicylate excreted to be determined 
• x = urine pH 
a = 2.613 x 10”5 
b = 7.14
The salicylate excretion for the standardised, mean pH of 6.2 was 
also calculated:
SA excretion = 2.613 x 10  ^* (pH 6.2^*^)
= 11.9
The corrected value for total salicylate excretion was then
determined as follows:
Corrected SA = (Observed SA - Expected SA) + SA excretion 
excretion excretion excretion at PH 6.2
In this way the majority of the variation in SA excretion due to 
urine pH was removed. Therefore, any variation remaining is 
probably due to factors other than urine pH.
ALL VALUES FOR SA EXCRETION ARE EXPRESSED AS CORRECTED SA VALUES 
UNLESS OTHERWISE STATED
Effect of age and weight
Table 3.1 gives the total amount and percentage dose of corrected 
SA and SUA excreted in 8 hours following a therapeutic dose of 
600 mg ASA. 15.01± 0.91 mg (3.26 ± 0.20%) of SA were excreted 
together with 193.4 ± 5.0 mg (42.24 ± 1.09%) of SUA. Individual 
results (expressed in mg) are given in Appendix 1 together with 
further details of the volunteers including sex, age, weight, 
smoking habits and drugs taken.
Table 3.1. Urinary recovery (0 - 8 hr) of SA and SUA following 
therapeutic dose in 150 normal volunteers.
Aspirin Total excreted % of dose Range
metabolite Mean ± SE Mean ±SE
SA 15.01 ± 0.91 mg 3.26 ±0.20% 0 - 59.9 mg
SUA 193.4 ± 5.0 mg 42.04 ± 1.09% 28.2-444.4 mg
No correlation was found between age and excretion of the 2 aspirin 
metabolites, SA and SUA as shown in Figs. 3.2a and b (r = 0.005, 
0.088 respectively, p > 0.1). Similarly, body weight and excretion 
of these 2 metabolites also failed to show a correlation as can be 
seen in Figs. 3.3 a and b (r = -0.204, 0.342 respectively, p > 
0.1).
Effect of gender
Urinary excretion of SA and SUA were compared in males and females 
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of the major metabolite SUA whilst females excreted a significantly 
lower amount of 163.1 ± 8.65 mg of SUA (p < 0.01).
For the minor metabolite, SA, males excreted 13.1 - 1.0 mg whilst 
females excreted a significantly higher amount of 17.8 ± 1.65 mg 
(p < 0.01). Figs 3.4a and b show the 8-hour urinary excretion of SA 
and SUA in both males and females.
Effect of smoking and oral contraceptive steroids
The excretion of the 2 ASA metabolites, SA and SUA was compared in 
smokers and non-smokers for both male and female. No significant 
difference was found between smokers and non-smokers in any of the 
groups studied, as shown in Figs. 3.5a and b and Table 3.2.
















SA 12.6±2.4 13.1+1.2 22.1± 5.8 17.511.95
SUA 207.9±9.55 216.816.7 135.45±30.3 166.319.9
For females using oral contraceptive steroids, 0CS, (n = 10) and
females not using oral contraception (n = 45) the excretion of SA 
and SUA was compared. 0CS users excreted 159.25 ± 7.0 mg SUA and
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18.3 ± 2.2 mg SA. These differences were found to be non­
significant as shown in Figs. 3.6a and b.
b) Genetic control of aspirin metabolism
Figs. 3.7a and b show the frequency distribution histograms and 
probit plots for the 8-hour urinary excretion of observed SA and 
corrected SA respectively. The distribution of observed SA 
excretion appeared to be strongly positively skewed as seen in the 
frequency distribution histogram. This skewness is confirmed in the 
probit plot which was found to be non-linear (x2 = 39.7, p < 0.01). 
The distribution of corrected SA excretion appeared to be 
approaching a normal distribution when the frequency distribution 
histogram was studied. However, the probit plot for this data was 
found to be non-linear (x2 =39.1, p < 0.01) indicating that the 
distribution may be skewed.
Fig. 3.8 shows the frequency distribution histogram and probit plot 
for the 0 to 8-hour urinary excretion of SUA. The frequency dis­
tribution histogram showed a negative skewness for the distribution 
of SUA excretion. However, the probit plot only just failed the 
test of linearity (x2 = 29.4, p < 0.05) and so the distribution is 
probably approaching normality and is only slightly skewed.
The Metabolic Ratio (MR) was calculated for each individual as 
follows:
Excretion of pH corrected SA (mg)
Metabolic Ratio = _______________________________
Excretion of SUA (mg)
Fig. 3.9 shows the frequency distribution histogram and probit plot
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strongly positively skewed distribution. This skewness is supported 
by the probit plot which was found to be non-linear (x2 =44.1,
p < 0.01).
Repeat studies
600 mg aspirin was taken a second time by 13 of the volunteers with 
6 months to 2 years between the 2 tests. Table 3.3 gives the mean 
values for excretion of SA, SUA and SA + SUA in the first and 
second determination. Between the 2 tests, SA showed a 72.6 ± 32.0%
change; SUA, a 22.8 ± 6.3% change and SA, + SUA a 22.1 1 5.6% change
(mean ± SE) •
Table 3.3. Urinary recovery (0 - 8 hr) of SA and SUA in 2 separate
tests for 13 subjects (mean 1 SE)
1st determination 2nd determination
Aspirin
Metabolite Total . % of dose Total % of dose
excreted excreted
(mg) (mg)
SA 15.8±4.45 3.4±1.0 20.815.4 4.511.2
SUA 194.0±11.7 42.2± 2.5 188.8114.6 41.013.2
SA + SUA 209.819.0 45.611.9 209.6115.7 45.613.4
The 1st estimates of the aspirin metabolites, SA (corrected) and 
SUA are plotted against the 2nd estimates in Figs. 3.10a and b 
respectively. Figs. 3.11a and b show the 1st and 2nd estimates of 
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of results seen in the reproducibility plots for SA excretion and 
the metabolic ratio are much greater than the spread seen in the 
plots for SUA and SA + SUA excretion. SUA and SA + SUA excretion 
was found to vary by 25% or less in 9 subjects (70% of the 
volunteers participating in the repeat study) whilst SA excretion
and the metabolic ratio, SA/SUA varied by 25% or less in only 2
subjects (15% of the 'repeat' volunteers).
3.4 DISCUSSION
Aspirin metabolism was studied in 150 normal volunteers following a 
therapeutic (600 mg) dose. After oral administration the 8-hour 
urine collection was analysed for SA and SUA. A mean of 42 ± 1.1% 
of the dose was excreted as SUA, with a mean of 3.3 ± 0.2% of the 
dose being excreted as SA (corrected for pH), which is in agreement 
with other workers including Bedford et at,, (1965), Cummings 
et at, (1966) and Caldwell et at, (1979).
Urine pH and salicylic acid excretion
The effect of urine pH on salicylate excretion as found by
Macpherson et at, (1955) and Gutman et at, (1955) who reported a
log-linear relationship, was confirmed in the present study. A
highly significant positive correlation (r = 0.732, p < 0.01)
between urine pH and observed SA excretion was found and in the pH
range studied (pH 5.0 to 8.0) an exponential curve was determined
as the best-fit for the data. The difference between this and the 
earlier reported relationship between urine pH and SA excretion is
probably due to the much larger numbers used in the present study.
A positive correlation between urine pH and SA excretion was 
expected as the renal clearance of SA is known to involve in 
addition to glomerular filtration and active secretion, passive 
back-diffusion into the renal tubules. Only the non-ionised form of 
SA is subject to tubular reabsorption. Therefore, as urine pH 
increases, so does the degree of SA ionisation resulting in 
decreased tubular reabsorption and finally increased urinary 
excretion of SA. As urine pH increases from 5 to 8, the renal 
clearance of SA has been found to increase more than 20-fold. As 
urine pH was known to have such a profound effect on SA excretion, 
in order to determine if any other factors under study cause any 
changes in SA excretion, the effect of pH had to be removed. This 
was done by correcting the salicylic acid excretion for pH whereby 
all.SA values were adjusted to the mean pH of 6.2 using the method 
given in 3.3a (a method also used by Whittaker and Price-Evans, 
1970, in correcting phenylbutazone half-life for height). In this 
way the majority of the variation remaining in SA excretion must be 
due to some factor other than urine pH.
Body weight and ASA metabolism
No correlation was found between body weight and excretion of SA 
(corrected for pH) or SUA. However, Cummings and Martin (1964) 
found a strong inverse relationship between plasma salicylate 
levels.and body weight in the 10 healthy males studied. As these 
workers did not report any correlation between body weight and
urinary excretion of salicylate, and plasma levels of SA were 
measured after steady-state was reached following chronic dosing 
with 1 g of aspirin per dose, their study and the present work are 
not directly comparable.
Age and ASA metabolism
No correlation was found between age and excretion of SA (corrected 
for pH) or SUA. However, this finding differs from reports by 
Montgomery et at, (1986), Netter et at. (1986) and Ho et at.
(1985). These studies showed that although there is no correlation 
between age and various pharmacokinetic parameters of SA, namely 
plasma clearance, maximal plasma concentration and AUC, significant 
positive correlations were found between age and the maximal plasma 
concentration and AUC of SUA. The effect of age on SUA is also 
supported by renal clearance data of Montgomery et at, (1986) and 
Ho et at. (1985). They found that renal clearance of SUA decreased 
with increasing age (p < 0.001), however they provide conflicting 
evidence for the renal clearance of SA. Ho et at. (1985) also 
showed that renal clearance of SUA correlated strongly (p < 0.001) 
with the renal clearance of creatinine. Therefore the decreased 
renal clearance and elevated plasma levels of SUA reported in the 
elderly are due to the age-related decrease in glomerular 
filtration rate (Kampmann et at., 1979). However, despite the 
effects of age on plasma levels and renal clearance of SA and SUA, 
the 24-hour urinary recovery of these 2 metabolites was not found 
to be affected by age.
The lack of correlation between age and the 8-hour urinary
excretion of SUA found in the present study, is probably due to the 
comparatively limited age-range of 18 to 61 years. In the studies 
by Montgomery et at. (1986), Netter et at. (1985) and Ho et at.
(1985), a higher age range was used where subjects up to 80 years 
of age participated in the studies. The necessity of increasing the 
age range to show a correlation between age and excretion of ASA 
metabolites was observed by Oldham (1983). In the lower age range 
of 21 to 65 years, no significant changes were observed between age 
and the 8-hour urinary excretion of aspirin metabolites, as 
confirmed in the present study. However, in the age range of 65 to 
85 years, SA secretion was found to decrease with age (p < 0.05). 
Therefore, as no elderly people over 65 years participated in the 
present study, no age effect on salicylate metabolism was observed.
Sex differences and ASA metabolism
Sex differences in salicylate metabolism were found in the present 
study for females excreted 24% less SUA (p < 0.01) and 36% greater 
SA (p < 0.01) compared to males, in the 0 to 8-hour urine 
collection. Trnavska and Trnavsky (1983), Ho et at. (1985) and 
Miners et at. (1986) found comparable differences in plasma levels 
of the aspirin metabolites as the plasma concentration of SA was 
found to be significantly higher in females whilst SA plasma 
clearance was significantly lower. Miners et at. (1986) and Ho et 
at. (1985) also found significantly decreased renal clearance of 
SUA in females but no sex difference in renal clearance of SA. The 
sex difference in renal clearance of SUA is confirmed in the 
present study where females were found to excrete significantly
less SUA. However, the lack of sex difference in renal clearance of 
SA was not reflected in the present study, where significantly more 
SA was excreted in females. This discrepancy may be due to the 
values obtained for the renal clearance of SA not being adjusted 
for pH. Therefore any differences due to gender are probably being 
masked by the variation due to urine pH: a variation removed in the 
present study.
Trnavska and Trnavsky (1983) and Ho et at. (1985) also found an 
elevated aspirin AUC and elimination half-life in females, 
apparently due to an intrinsically lower activity of aspirin 
esterase in females.
Oral contraceptive steroids and ASA metabolism 
Oral contraceptive steroids were found to have no effect on the 
8-hour urine excretion of SA and SUA. However Gupta et at. (1982) 
found that salicylic acid AUC was significantly reduced in women 
who had used OCS for 2 months. Miners et at. (1986) supported this 
by finding that the half-life of SA was significantly decreased in 
OCS users compared to control females. The metabolic and renal 
clearance of SUA was also found to be significantly greater in OCS 
users. Therefore Miners et at. stated that the increased SA plasma 
clearance found in OCS users was due to increased glycine conju­
gation. However the present study does not support the results of 
Miners et al. and Gupta et at. as oral contraceptives were not 
found to induce the glycine conjugation of SA.
One reason for the contrasting results could be that the subjects
of Miners et al. were approaching basal conditions whereas the 
subjects of the present study represent a normal female population. 
Also, Miners et at. used 8 females in the OCS group and 8 in the 
control female group, whilst the present study 10 females used OCS 
and 45 were control females. These differences in the range and 
number of subjects used are reflected in the larger interindividual 
variations found in the present study.
Also Gupta et al, discovered that although plasma levels and the 
half-life of SA are decreased during short-term OCS use, during 
long-term use (of 2 years or greater) these factors return to the 
basal levels found in control females. As no details were taken 
concerning length of oral contraceptive use in the present study, 
differences in the length of OCS use may also account for the 
contrasting results.
Although Miners et al, and Gupta et al, have shown oral contr­
aception to cause an increase in glycine conjugation of SA, the 
present work indicates that this indication cannot be observed when 
a normal relatively large population is observed. Therefore, the 
inductive effect of OCS on salicylate metabolism may be of little 
clinical importance.
Smoking and ASA metabolism
Smoking was found to have no effect upon ASA metabolism in the 
present study.
Cigarette smoke contains polycyclic hydrocarbons which are known to 
be potent enzyme inducers. Evidence has shown that polycyclic 
hydrocarbons are capable of increasing the activity of several
enzyme systems in liver microsomes, including N-demethylation, 
hydroxylation, reduction and glucuronide conjugation (Conney and 
Burns, 1962), although considerable substrate specificity is 
exerted. Smoking may have no effect upon the metabolism of SA, 
despite the constant exposure to polycyclic hydrocarbons, because 
the major metabolic pathway of SA, glycine conjugation, is non- 
microsomal. The enzyme system is situated in the hepatic 
mitochondria and polycyclic hydrocarbons appear to be potent 
microsomal enzyme inducers.
b) Genetic control of aspirin metabolism
Large interindividual differences in serum concentrations and 
elimination rate of SA and SUA have been reported and were also 
found in the present study. 0 to 13% of the given dose (600 mg ASA) 
was excreted as SA, with 6 to 96% of the dose excreted as SUA in 
the 8-hour urine collection. Similar ranges were also found by 
Caldwell et at, (1980) where 1 - 10% of the dose (900 mg ASA) was 
excreted as SA and 6 - 72% excreted as SUA in a 12-hour urine 
collection. Such large variations in salicylate levels have been 
reported by several workers. Levy and Hollister (1964) found 
salicylate half-life varied from 2.5 to 8.5 hours in the 17 healthy 
subjects studied. Similarly, Paulus et al, (1971) and Gupta et al, 
(1975) found 5-fold variations in serum SA levels in rheumatoid 
arthritis patients following chronic dosing with aspirin. Gupta 
et al, also studied the urinary excretion of ASA metabolites and 
established a strong correlation between maximum serum SA levels
and the urinary excretion of SUA. Therefore, they proposed that the 
interindividual differences in serum levels are determined, at 
least partly, by similar differences in maximum rates of SUA 
formation and excretion.
In the present study, observed SA excretion was found to be 
positively skewed. This deviation from a normal distribution 
indicates that one or more factors have a predominant control on SA 
excretion, which is to be expected as SA secretion is, at least 
partly, a function of pH. The distribution of corrected SA 
excretion was also found to be skewed but it was much nearer to a 
normal distribution than that of observed SA excretion, showing 
that the majority of the effect of urine pH on SA excretion had 
been removed. The distribution of SUA was also found to be skewed. 
Therefore corrected SA and SUA excretion are subject to polygenic 
and multifactorial control with one or more factors having a 
predominant influence. Significant sex differences in salicylate 
metabolism have been found in the present study and these could be 
one of the factors responsible for the skew distribution of 
corrected SA and SUA.
The metabolic ratio SA/SUA was determined for each individual as 
this is a further way of expressing the glycine conjugation 
capacity of an individual. It is a more sensitive assessment of SA 
metabolism when compared to the excretion of the major metabolite, 
SUA, as relatively more importance is given to the individual 
excreting smaller amounts of SUA. The distribution of the metabolic 
ratio was found to be strongly skewed and had no discrete sub­
groups but was a wide and continuous spread. The deviation from a 
normal distribution and the interindividual variation of the 
metabolic ratio are sufficiently large to indicate that there may 
be genetic control of SUA formation and excretion. However, as the 
distribution is not multi-modal and no discrete sub-groups found, 
genetic control cannot be isolated from environmental control.
In order to test the possibility of genetic control of salicylate 
metabolism further, a repeat study was performed in 13 subjects.
70% of the subjects tested excreted similar amounts of SUA in the 2 
tests whereas only 15% of the subjects excreted similar amounts of 
corrected SA on each occasion, and hence only 15% of the subjects 
had similar metabolic ratios for each occasion. Although SUA 
excretion was found to be largely reproducible, large intra­
individual variations of 25 - 60% exist in 30% of the subjects. 
Also, the reproducibility of corrected SA excretion and the 
metabolic ratio was very poor with .large intra-individual 
variations of 25 to 400% and 25 to 500% respectively occurring in 
85% of the subjects. Plus, although the time difference between 
repeat tests varied from 7 to 27 months, it ap'peared to have no 
effect upon the reproducibility obtained.
Therefore, although the wide, skewed distribution obtained for the 
metabolic ratio indicated that there may be genetic control of SA 
metabolism, the lack of reproducibility shows that any genetic 
control present must be comparatively weak. Hence although genetic 
control may be partially responsible for the skewed distribution 
found for glycine conjugation of SA, further environmental factors
may also be responsible for this deviation from a normal distri­
bution. The lack of reproducibility further indicates that environ­
mental factors may have a stronger influence on salicylate 
metabolism. The reproducibility results of SUA found in the present 
study, are supported by Levy and Hollister (1964) where serum 
elimination rate constants of SA were found to differ by a maximum 
of 20% in 70% of subjects studied (12 out of 17) in repeat tests. 
When these results are combined with the strong correlation between 
maximum serum SA levels and SUA urine excretion (as found by Gupta 
et al., 1975), they provide similar values of reproducibility to 
those obtained in the present study.
Large variations in serum SA levels and the reproducibility of 
serum levels of SA indicate that there may be genetic control of SA 
metabolism. However, when Evans and Clarke (1961) studied the 
possibility of polymorphism of salicylate metabolism, serum levels 
determined 3 hours after ingestion of sodium salicylate showed a 
normal distribution. Therefore, despite the large variation, Evans 
and Clarke could detect no polymorphism of serum salicylate levels. 
The lack of clear genetic control was also found by Caldwell 
et al. (1980) and Hutt et al. (1986). In these population studies 
(n = 85 and n = 129 respectively) a unimodal distribution of SUA 
excretion was found, with the distribution presented by Hutt 
et al. appearing slightly skewed (although the probit plot showed a 
normal distribution) Hutt et al. also showed a skewed distribution 
for SA excretion, similar to that obtained in the present study for 
observed SA excretion, and so the deviation from a normal 
distribution is probably mainly due to urine pH. Caldwell et al.
performed reproducibility studies on 6 of their subjects and they 
found that the relative extent of glycine conjugation (that is, SUA 
excretion being expressed as a percentage of the total salicylate 
excreted) only varied by a maximum of 12%. The discrepancy between 
these reproducibility results and the results of the present study 
are due to relative amounts being expressed in the former and 
absolute amounts expressed in the latter. Caldwell et al. stated 
that total recovery of SA (and therefore recovery of the major 
metabolite, SUA) varied, but the extent of variation was not 
reported.
The population studies performed on serum SA levels (Evans and 
Clarke, 1961) and urinary salicylate metabolites (Caldwell et at,, 
1980; Hutt et al, , 1986) all failed to show polymorphism of 
salicylate metabolism. The lack of clear genetic control was also 
confirmed in the present study.
However, Furst et al. (1977) did find some indication of genetic 
control when studying salicylate metabolism in fraternal and 
identical twins. Intrapair variation in maximum serum SA levels and 
plasma clearance of SA were significantly less for identical twins 
than for fraternal twins in both acute IV and chronic oral dosing. 
Intrapair variation in SUA excretion rate and Vmax was signi­
ficantly less in identical twins on chronic oral dosing alone. 
Hence, this study shows that there may be some genetic control of 
aspirin metabolism, as determined from both plasma and urinary 
data. It must be noted that the subjects taking part in the study 
of Furst et al. were hospitalised prior to the study and so 
environmental variation was kept to a minimum, unlike the
population studies where normal day-to-day routine was not 
interrupted.
Further support for possible genetic control of ASA metabolism is 
given by Emudianughe et al. (1986). A population study of 122 
Nigerians was performed and wide variations in SUA and salicylic 
acid glucuronide (SAG) excretion were found. The SUA/SAG ratio was 
found to be significantly higher in Caucasians than in black 
Nigerians, suggesting that Caucasians have a higher capacity for 
glycine conjugation. Such a racial difference in turn implies 
genetic control.
Despite the work by Furst et al. (1977) and Emudianughe et al.
(1986), no firm evidence has been provided for the genetic control 
of aspirin metabolism, as various population studies, including the 
present work, have failed to show any polymorphism. This is 
probably due to a number of other factors which affect aspirin 
metabolism and which mask any genetic control that may be present. 
In the present study, sex has been found to have a significant 
effect on ASA metabolism although there is conflicting evidence 
concerning the effect of age, body weight and oral contraceptive 
steroids. Recent reports have shown that fasting or not fasting 
prior to aspirin ingestion had no effect upon aspirin bioavaila­
bility (Koch et al. y 1986) and caffeine intake, although increasing 
aspirin bioavailability, had no effect upon salicylate excretion 
(Yoovathaworn et al., 1986).
Therefore, age (if greater than 65), sex and urine pH are the only 
factors known to affect SA metabolism. Further investigation must
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be performed in order to determine further causes of the wide 
inter- individual variation of salicylate metabolism.
CHAPTER FOUR
PARACETAMOL METABOLISM IN HUMAN VOLUNTEERS 
4.1 INTRODUCTION
Several studies have been performed in order to determine the 
effects of various environmental factors on paracetamol metabolism 
(including Mucklow et al., 1980; Miners et al., 1983). However, few 
workers have studied the possibility of genetic control of paracet­
amol metabolism. In the present study a therapeutic dose of para­
cetamol was given to a large number of healthy adult volunteers and 
the urinary excretion of free paracetamol (P) and its major meta­
bolites; paracetamol glucuronide (PG) and paracetamol sulphate (PS) 
were determined. In this way the effects of various environmental 
factors on paracetamol metabolism were determined and the 
possibility of genetic control investigated.
4.2 PROCEDURE
Paracetamol (1 g) was taken orally in the morning by 99 volunteers, 
68 male and 31 female, after first voiding their bladders. An 0 - 
8 hr urine collection was obtained and the urinary metabolites 
paracetamol (P), paracetamol glucuronide (PG) and paracetamol 
sulphate (PS) were assayed by HPLC as described in Chapter 2.8a.
The quantity of PG and PS excreted is expressed as the equivalent 
weight of P, using the correction factors given in Chapter 2.12.
The age range for males was 18 to 60 years with a mean age of
36.5 ± 1.4 years (mean ± SE) and the weight range was 48 to 102 kg 
with a mean weight of 74.9 ± 1.4 kg (mean ± SE). The age range for 
females was 19 to 57 years with a mean age of 34.5 ± 1.9 years 
and the weight range was 47 to 95 kg with a mean weight.of
60.6 ± 2.1 kg.
The Student's t test was used as the test for statistical 
significance throughout this study.
4.3 RESULTS
a) Environmental control of paracetamol metabolism
Table 4.1 gives the total amount and percentage dose excreted in 8 
hours of P, PG and PS, following a therapeutic dose of 1 g of 
paracetamol. 21.0 ±0.9 mg (2.1 ± 0.1%) of free paracetamol was
excreted, together with 427.9 ± 11.1 mg (42.8 ± 1.1%) of PG and
217.5 ±8.6 mg (21.75 ± 0.9%) of PS. In total, 660.9 ± 15.5 mg 
(66.1 ± 1.55%) of the dose was recovered in the 8-hour urine. 
Individual results (expressed in mg) together with the sex, age, 
weight, smoking habits and concomitant drug treatment of each 
volunteer are given in Appendix 2.
Figs. 4.1 and 4.2 show the relation between the 8-hour urinary
excretion of the 2 major paracetamol metabolites, PG and PS. No 
correlation was found between the total amounts of PG and PS 
excreted (r = 0.102, p > 0.1, Fig. 4.1). However, when PG and PS 
were expressed as the percentage of dose recovered, a strong 
negative correlation was found between the two metabolites (r =0*924 
p < 0.01, Fig. 4.2).
F T G U P F  4.1
Relationship between the urinary excretion of PG and PS 
(expressed as the total amount recovered)
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Table 4.1. Urinary recovery (0-8 hr) of paracetamol and its





mean ± SE 
(mg)
% Dose excreted 




PG 427.9 ± 11.1 42.79 ± 1.11 194.8 - 715.4
PS 217.5 ± 8.6 21.75 ± 0.86 71.3 - 560.5
P 21.0 ± 0.9 2.10 ± 0.09 3.7 - 60.5
PG + PS + P 660.9 ± 15.5 66.09 ± 1.55 268.1 - 1152.0
Effect of age and weight 
Urinary excretion of P, PG and PS all failed to show a correlation
with age (r = 0.066, -0.260, 0.202“ respectively, p > 0.1). Similarly,
excretion of P, PG and PS also failed to show a correlation with body 
weight (r = 0.004, -0.082, 0.007 respectively; p > 0.1). The 
relationships between age and weight and the urinary excretion of P, 
PG and PS are shown in Figs. 4.3 to 4.5.
Effect of gender
The urinary excretion of the paracetamol metabolites, P, PG and PS 
was compared in males and females. No significant difference was 
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Table 4.2. Urinary excretion (0 - 8 hr) of paracetamol and its
metabolites (mean - SE) in males and females.
Paracetamol
metabolite
Male (n = 68) 
(mg)
Female (n = 31) 
(mg)
PG 414.0 ± 12.7 449.0 ± 21.8
PS 212.0 ± 9.0 229.5± 19.3
P 21.6 ± 1.0 19.7 ± 1.9
Effects of smoking
The effect of smoking on urinary excretion of paracetamol and its 
metabolites was assessed. Male smokers and male non-smokers showed no 
significant difference in the urinary excretion of P, PG and PS. 
Female smokers also showed no significant difference in the urinary 
excretion of P and PS compared to female non-smokers. However, female 
smokers were found to excrete significantly more PG than female 
non-smokers. These results are shown in Table 4.3 and Fig. 4.6.
FIGURE 4.6 109.
Effect of smoking bn the 0-8 hr urinary excretion
of paracetamol and its major metabolites, PG and PS
in males and females.
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Table 4.3. Urinary excretion of paracetamol and its metabolites













PG 414.8 ± 15.2 401.1 ± 22.0 *406.6 ± 22.9 539.7 ± 55.6
PS 209.8 ± 10.4 216.2 ± 19.6 240.7 ± 23.1 345.8 ± 57.1
P 21.5 ± 1.2 21.5 ± 2.0 18.5 ± 2.0 29.8 ± 8.1
* p <0.02 when compared to smoker.
N.B. The female smokers and non-smokers are all control females. 
i.e. None of the females in the above table (Table 4.3) use 
oral contraceptives.
Effect of oral contraceptive steroids
In order to study the effects of oral contraception on paracetamol 
metabolism, the data obtained from OC users (all non-smokers) was 
compared with males and non-smoking females (due to the significant 
effect of smoking on paracetamol metabolism in females).
Oral contraceptive steroid (OCS) users were found to excrete more 
PG than males and control females but the differences just failed 
to reach significance (p > 0.05). Conversely, OCS users excreted 
significantly less PS than both males and control females 
(p < 0.02 ). No significant difference was found in P excretion 
between any of the 3 groups studied (p > 0.1). These differences 
are shown in Table 4.4 and Fig. 4.7.
FIGURE 4.7
Urinary excretion of paracetamol and its major
metabolites in males, females using OCS and
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Table 4.4. Urinary excretion of paracetamol and its metabolites
(mean ± SE) in males, females using oral contraceptive 
steroids (OCS users) and females not using OCS.
Paracetamol Males OCS users Control females
metabolite (n=68) (n=ll) (n=15)
PG 414.0 ± 12.7 483.9 ± 38.2 406.6 ± 22.9
PS *212.0 ± 9.0 161.6 ± 17.7 *240.7 ± 23.1
P 21.6 ± 1.0 17.4± 2.3 18.5 ± 2.0
* p< 0.02 when compared to OCS users, 
b) Genetic control of paracetamol metabolism
Figures 4.8 to 4.10 show the frequency distribution histograms and 
probit plots for the urinary excretion of unchanged paracetamol, PG 
and PS respectively. The linear probit plots for P and PG excretion 
(x2 = 19.4, 13.3 respectively; p > 0.1) together with their 
frequency distribution histograms, show a normal distribution for 
these 2 urinary metabolites. However, the frequency distribution of 
PS excretion appears to be slightly skewed, with the deviation from 
a normal distribution being supported by the non-linear probit plot 
(x2 = 26.5, p < 0.01).
The metabolic ratios were then determined for each individual to 
further assess the glucuronidation and sulphation capacities of the 
subjects and these were calculated as shown below:
FIGURE 4.8
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Total amount of unchanged P 
excreted (mg)
Total amount of PG excreted 
(mg)
Metabolic Ratio; P/S 
(Sulphation Ratio)
Total amount of unchanged P 
excreted (mg)
Total amount of PS excreted 
(mg)
The frequency distribution histograms and probit plots for the 
metbolic ratios, P/PG and P/PS are shown in Figures 4.11a and 
4.11b. The histograms for both ratios are normally distributed, 
with the linear probit plots (x2 = 18.1 for P/PG; p > 0.1 and 
x2 =9.1 for P/PS; p >0.1) confirming the normal distribution.
A further metabolic ratio, PG/PS was calculated in order to study 
the relative capacities of glucuronidation and sulphation for each 
individual.
Metabolic Ratio, PG/PS _ Total amount of PG excreted
(Relative conjugation ratio) ________ ________________
The frequency distribution histogram given in Figure 4.12 appears 
strongly skewed, and the non-linear probit plot (x2 = 20.6, p < 
0.05) supports the deviation from a normal distribution.
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a) Environmental control of paracetamol metabolism
Following oral administration of 1 g of paracetamol to 99 healthy 
volunteers, the 0 - 8  hour urinary excretion of P, PG and PS was 
determined. PG and PS were found to be major metabolites of 
paracetamol, with 42.8 ± 1.1% of the dose excreted as PG,
21.75 ±0.9% excreted as PS and 2.1 ± 0.1% excreted as unchanged P. 
In total, 66.1 ± 1.55% of the dose was recovered as P + PG + PS in 
the 0 - 8  hour urine. These results are similar to those of 
Cummings et at. (1967) and Potter et at. (1974), who found similar 
urinary excretions for paracetamol and its 2 major metabolites, PG 
and PS.
As PG and PS are the 2 major paracetamol metabolites, the relation­
ship between the two was studied in the present work. No correla­
tion was found between the total urinary excretion (expressed in 
-mg) of PG and PS. However, there were large interindividual 
variations found in the urinary excretion of PG and PS which may 
have masked possible intraindividual correlation between the 
metabolites. Thus, the urinary excretion of both PG and PS were 
expressed as a percentage of the dose recovered in the 0 - 8  hour 
urine. In this way, the large interindividual variation in the 
total percentage of dose excreted is removed, and so any 
intraindividual relationship between PG and PS can be observed. A 
strong negative correlation (p < 0.01) was found between PG and PS 
excretion when they were expressed as a percentage of the dose 
recovered. This strongly suggests that the 2 pathways, glucuron
idation and sulphation are in competition with each other during 
the metabolism of p air ace tamo 1. Oldham (1983) reported similar 
findings.
Effect of age
In the present study no significant correlation was found between 
age sind the 0-8 hour urinary excretion of P, PG and PS. Similarly, 
Mucklow et at. (1980) failed to find a correlation between age and 
paracetamol plasma clearance and paracetamol half-life. In both 
studies, the subjects were aged from 18 to 60 years.
However, Briant et at. (1975), Rawlins et at. (1979) and Triggs
et at, (1975), have all shown that subjects over 65 years old have 
significantly longer paracetamol half-lives when compared with 
subjects under 40 years old, indicating that the elderly subjects 
may have impaired paracetamol metabolism. Triggs et at. also 
studied the urinary excretion of paracetamol and its metabolites 
and although the percentage of dose excreted in 24 hours was 
similar in both young and elderly, the percentage of conjugated 
paracetamol excreted was much more variable in the elderly. 
Therefore, they suggested that conjugation may be impaired in some 
elderly subjects. The data presented here, together with that of 
Mucklow et at., indicates that the capacity for paracetamol 
conjugation is not affected by age in subjects 18 to 62 years old. 
However, the data presented by Briant et at., Rawlins et at. and
Triggs et at. suggests that the capacity for paracetamol 
conjugation is decreased in subjects older than 65 years. 
Therefore, the lack of effect of age on paracetamol metabolism,
found in the present study, is probably due to the relatively young 
age range studied. For the effect of age on paracetamol metabolism 
to be noticedj subjects aged over 65 years should be included in 
the study.
Effect of body weight
The present study showed that no correlation was found between body 
weight and 8 - hour urinary excretion of P, PG and PS. Therefore, 
body weight was found to have no effect upon paracetamol 
metabolism. This is supported by Mucklow et at, (1980), who also 
failed to find correlations between body weight and paracetamol 
plasma clearance and paracetamol half-life.
Effect of gender
Males and females were found to excrete similar amounts of 
paracetamol and its major metabolites, PG and PS, in the present 
study. Similarly, Miners et at, (-1980) and Mucklow et at, (1980) 
both found paracetamol plasma clearance to be significantly higher 
in males than females, although the half-life of paracetamol was 
found to be similar in both sexes. Furthermore, Miners et at, found 
that the renal and metabolic clearance of PG was significantly 
higher in males. Therefore, Miners et at, stated that the increased 
paracetamol clearance found in males is due to increased glucuron­
idation.
However, despite the increased paracetamol clearance found in 
males, Miners et at, found that this sex difference is not 
confirmed in the total urinary excretion of the paracetamol
metabolites and similar results to those of the present study were 
obtained. As paracetamol half-life and total urinary excretion of 
paracetamol and its major metabolites, PG and PS have been found 
not to differ between males and females, the sex differences found 
by other workers are probably of little clinical significance.
Effect of smoking
Smoking was found to have no significant effect upon the urinary 
excretion of PS and P in both males and females. However, although 
smoking did not affect PG excretion in males, PG excretion was 
found to be significantly higher in female smokers than in female 
non-smokers. Therefore, smoking was found to increase paracetamol 
glucuronidation in the female but had no effect upon paracetamol 
metabolism in the male.
The inductive effect of smoking on paracetamol metabolism found in 
the present study is supported by Mucklow et at, (1980) who found 
plasma paracetamol clearance to be significantly higher in smokers 
than non-smokers.
Cigarette smoke contains polycyclic hydrocarbons which are known 
to be potent enzyme inducers. Polycyclic hydrocarbons have been 
found to increase the activity of several microsomal enzyme systems 
involved in Phase I metabolism, including N-demethylation, hydroxy- 
lation and reduction (Conney and Burns, 1962). Hamada and Gessner, 
1975, have shown that the polycyclic hydrocarbon, 3-methylcholan- 
threne increases UDP-glucuronyltransferase activity in rats, whilst 
Uotila and Marrierni, 1976, have demonstrated increased glucuron­
idation in the rat lung following inhalation of cigarette smoke for
1 hour.
These studies indicate that, in rats, cigarette smoke is capable of 
inducing a wide variety of microsomal enzymes, including UDP-gluc- 
uronyltransferase. Therefore, the increased paracetamol plasma 
clearance found in smokers (Mucklow et at., 1980) is probably due 
to the induction of the major metabolic pathway, namely 
glucuronidation. This is supported by the present study where 
female smokers were found to excrete increased amounts of the major 
metabolite, PG, indicating induced glucuronidation in these 
subjects.
Effect of oral contraceptive steroids
The present study indicated that urinary excretion of PG tended to 
be higher in OCS users, but possibly due to the large interin­
dividual variation, this failed to reach significance. Urinary 
excretion of PS was found to be significantly reduced in OCS users, 
whilst urinary excretion of free paracetamol was similar in OCS 
users and control females. As the present study has shown gluc­
uronidation and sulphation of paracetamol to be competing pathways, 
the significant decrease in PS excretion found in OCS users has to 
be accompanied by an increase in PG excretion in these women.
Hence, in the present study, OCS have been found to alter the 
metabolism of paracetamol whereby the urinary excretion of PG was 
increased and PS excretion was decreased. The question arises as to 
whether the OCS inhibit sulphation resulting in increased 
glucuronidation or whether^ they induce glucuronidation resulting in 
decreased sulphation.
The results of the present study are supported by Abernethy et at. 
(1982); Miners et at. (1983); Mitchell et at, (1983) and Mucklow 
et at, (1980). They found that OCS cause increased plasma clearance 
and a shorter half-life of paracetamol. Furthermore Miners et at. 
and Mitchell et at. found that OCS caused an increase in the 
metabolic clearance of PG, but had no effect upon the metabolic 
clearance of PS and free P. Therefore they concluded that the 
increased paracetamol metabolism found in OCS users is due to 
induction of the glucuronidation pathway.
Therefore the increased PG excretion and decreased PS excretion 
found in OCS users in the present study may be indicative of 
induction of paracetamol glucuronidation as opposed to inhibition 
of paracetamol sulphation.
b) Genetic control of paracetamol metabolism
The present study showed considerable interindividual variation in 
the 0 - 8  hour urinary excretion of unchanged P and its 2 major 
metabolites, PG and PS. A 4-fold variation in PG excretion was 
obtained (with 19.5 to 71.5% of the dose excreted as PG). PS 
excretion varied 8-fold (7.1 to 56.0% of the dose excreted as PS) 
and unchanged P excretion varied 16-fold (0.4 to 6.0% of the dose 
excreted as P). Similar variations were also found by Caldwell 
et at. (1980) where the urinary excretion of P, PG and PS was 
studied in 34 healthy young adults.
Genetic control of glucuronidation
Normal distributions were found for both total PG excretion and the 
metabolic ratio, P/PG. Therefore the glucuronidation capacity of 
the population studied is probably not subject to monogenic control 
but is rather controlled and influenced by a number of genetic and 
environmental factors.
However, glucuronidation of a number of substrates does appear to 
be under monogenic control, as seen when individuals with Gilbert's 
syndrome are studied. Gilbert's syndrome is an inherited disorder, 
present in about 5% of the population. It is characterised by 
assymptomatic unconjugated hyperbilirubinaemia. The elevated 
bilirubin levels found in Gilbert's syndrome are mainly due to 
decreased hepatic uptake of bilirubin from plasma, and more 
importantly, decreased UDP-glucuronyltransferase activity 
(Macklon et at., 1979). As Gilbert's syndrome is an autosomal 
dominant trait, glucuronidation of bilirubin and certain other 
substrates is subject to monogenic control.
The metabolism of several compounds which undergo glucuronidation, 
have been found to differ in subjects with Gilbert's syndrome 
compared to those who do not have the syndrome, including menthol 
(Beck and Kiani, 1960) and estradiol benzoate (Aldercreutz and 
Tikkanen, 1973). Conversely, the plasma half-life and clearance of 
oxazepam and lorazepam were found to be unaltered in subjects with 
Gilbert's syndrome even though these 2 benzodiazepines also undergo 
glucuronidation.
Paracetamol metabolism has also been studied in subjects with 
Gilbert's syndrome (Douglas et at. 3 1978). Paracetamol plasma
clearance and the volume of distribution were fourid to be lowered 
in these subjects, although the half-life was not altered. 
Therefore, as the paracetamol half-life is unaffected by Gilbert's 
syndrome, the question arises as to whether the urinary excretion 
of PG, one of the major metabolites of paracetamol, would be 
expected to be lowered.
The present study showed a continuous distribution for paracetamol 
glucuronidation (when expressed as either the total urinary 
excretion of PG or as the metabolic ratio P/PG) with no isolated 
sub-group of "poor glucuronidisers". This could be due to the 
population studied not containing any subjects with Gilbert's 
syndrome (although from a population of 99 there would be an 
expected number of 5). Or, Gilbert's syndrome has no effect upon 
paracetamol glucuronidation and different forms of UDP-glucuronyl- 
transferase sire involved in bilirubin and paracetamol metabolism.
As at least 2 forms of UDP-glucuronyltransferase has been isolated 
in the rat liver (Burchell, 1977), the latter explanation for the 
unimodal distribution obtained in the present study, seems the most 
probable. Studies performed in msm also indicate that several 
isozymes of UDP-glucuronyltrsinsferase may exist. For example, 
oxazepam and temazepam have both shown sex differences, whereas 
lorazepam does not, even though all three are benzodiazepines and 
undergo glucuronidation. Similarly, the metabolism of estradiol and 
menthol were altered in Gilbert's syndrome but the metabolism of 
oxazepam and lorazepam were not, even though they too all undergo 
glucuronidation. The difference in response to gender and Gilbert's 
syndrome, depending upon the substrate indicates the multiplicity
of the glucuronidase enzyme(s). Therefore, the absence of an 
isolated sub-group of "poor glucuronidisers" in the population 
studied, is probably due to different forms of UDP-glucuronyl- 
transferase being involved in the metabolism of bilirubin and 
paracetamol.
Genetic control of sulphation
Total PS excretion and the metabolic ratio P/PS were both found to 
have continuous, unimodal distributions. This indicates that 
sulphation is subject to multifactorial and polygenic control. 
Although the distribution of PS excretion was found to be slightly 
skewed, this deviation from a normal distribution was not supported 
by the metabolic ratio P/PS and so is of little importance. 
Therefore, sulphation is probably not subject to monogenic control, 
but it is influenced by a number of genetic and environmental factors.
The metabolic ratio PG/PS showed a strongly skewed distribution. 
This indicates that the ratio is subject to polygenic and 
multifactorial control with one or more factor(s) having a 
predominant influence. As the distribution is positively skewed, 
either paracetamol glucuronidation is increased and/or paracetamol 
sulphation is decreased in a percentage of the population.
The present study has shown glucuronidation and sulphation of 
paracetamol to be competing pathways. Therefore, the metabolic 
ratio, PG/PS is a sensitive method for assessing genetic and 
environmental control of paracetamol glucuronidation and 
sulphation as an increase in one metabolite will generally result
in a decrease in the other.
The present study has shown that paracetamol metabolism is affected 
by smoking and oral contraceptives, both of which have been found 
to increase paracetamol glucuronidation. Hence, both smoking and 
OCS influence the metabolic ratio, PG/PS and these environmental 
factors could be partly responsible for the deviation from a normal 
distribution.
The skewed distribution for the ratio PG/PS could also indicate 
that there may be monogenic control of the conjugation pathways, 
but the strong influence of environmental factors on paracetamol 
metabolism may prevent a polymodal distribution from being seen. 
That is, the interaction of genetic and environmental factors 
results in the distribution of the ratio being skewed.
There is some evidence indicating that paracetamol metabolism may 
be under genetic control. Mucklow et at. (1980) found that 
paracetamol clearance and half-life were decreased in Asians 
compared to Caucasians. However, they stated that the major cause 
of this apparent racial difference was due to contrasting use of 
social drugs, including alcohol, tobacco and the contraceptive 
pill. However, Sommers et at. (1985) studied paracetamol metabolism 
in African villagers and found that paracetamol clearance was 
significantly increased when compared to the Asians studied by 
Mucklow et at. As both the Africans and Asians had minimal use of 
social drugs and both were vegetarians, environmental factors 
cannot explain the racial difference found. Therefore, it would 
appear that this ethnic variation is indicative of genetic control 
of paracetamol metabolism. Further indications of genetic control
were found by Caldwell et al. (1980) and Shively and Vesell (1975) 
who found that paracetamol metabolism was highly reproducible in 
subjects studied on 2 separate occasions.
Therefore, glucuronidation and sulphation of paracetamol may be 
subject to genetic control although the present study provides no 
supporting evidence. The glucuronidation and sulphation ratios,
P/PG and P/PS, are both normally distributed indicating polygenic 
and multifactorial control. It is only the more sensitive ratio, 
PG/PS, which shows a skewed distribution, indicating the 
predominant control of one or more factors. Environmental factors 
have been found to be at least partly responsible for this 
deviation from a normal distribution, and if any genetic factors do 
contribute to this deviation, their influence is not great enough 
to be of any clinical importance.
CHAPTER FIVE 
THE EFFECT OF CHRONIC ORAL CONTRACEPTIVE USE ON 
ENDOGENOUS ESTRADIOL METABOLISM
5.1 INTRODUCTION
Approximately 60 million women world-wide use oral contraceptive 
steroids. The most common formulations are the combined oral 
contraceptive agents which contain an estrogen and a progestogen. 
Prolonged use of the combined oral contraceptive pill has been 
found to alter the metabolism of a wide variety of exogenously 
administered compounds including antipyrine (Abernethy and 
Greenblatt, 1981), diazepam (Abernethy et at., 1982) and para­
cetamol (Miners et at., 1983). However, there have been few reports 
on the effects of oral contraceptive steroids (OCS) on the meta­
bolism of the endogenous steroid estradiol, and these include 
Longscope et at. (1974) and Femino et at. (1974), studying the 
effect of OCS use on estradiol clearance in females and Slikker 
et at. (1983) studying the effect of OCS use on the clearance and 
metabolism of estradiol in monkeys.
The endogenous hormone estradiol is the most active natural 
estrogen and is also very similar in structure to ethinyl estra­
diol, EE^ , the most common estrogenic component of the OCS. In 
order to study the effects of chronic OCS use on endogenous 
metabolism, estradiol was the endogenous compound of choice. 
Estradiol undergoes numerous metabolic transformations (see Figure 1. 
4) with the majority undergoing phase I transformation into the
less active compounds, estrone and estriol, both of which are 
further inactivated by phase II metabolism. A small percentage of 
estradiol (approx. 2 - 4%) is subject to direct inactivation by 
phase II metabolism (Beer and Gallagher, 1960; Femino et at., 1974) 
and it is the direct sulphate and glucuronide conjugation of 
estradiol which was examined in the present study. In this way, the 
effect of chronic OCS use on the phase II metabolism of an 
endogenous compound, the hormone estradiol,. was studied.
5.2 PROCEDURE
37 women who had used oral contraceptive steroids for a minimum of 
6 months (OCS users) and 8 women who had never used oral contra­
ception (control females) participated in the study. A single 10 ml 
blood sample and a 24-hour urine were obtained during the later 
phase of the menstrual cycle. For the OCS users, samples were taken 
from day 18 to day 21 (i.e. at the end of the pill-taking cycle) 
whilst for control females samples were taken from day 19 to day 22 
(i.e. around the estradiol peak of the luteal phase). Plasma 
estradiol together with urinary free estradiol (E^ ), estradiol 
glucuronide (E^ G) and estradiol sulphate (E^ S) were assayed by RIA 
as described in Chapter 2.
The mean age of the OCS users was 21.4 ± 0.5 years (with a range of 
18 - 32 years) and their mean weight was 59.7 ± 1.1 kg (with a 
range of 48 - 75 kg). Similar values were found with the control 
females. They had a mean age of 22.75 ± 1.5 years (with a range of
21 - 32 years) and a mean weight of 61.75 ±2.9 kg (with a range of 
53 - 72 kg). Individual details of the females who participated in 
this study, concerning age, body weight, concomitant drug treat­
ment, length and type of OCS use are given in Appendix 3. The 
Mann-Whitney test was used throughout this study as the test for 
significance.
5.3 RESULTS
The plasma estradiol concentrations of both control females and OCS 
users are given in Table 5.1 and Figure 5.1. The plasma concentra­
tion found in the OCS users was significantly lower than those of 
the control females (p < 0.001).
Table 5.1. Plasma estradiol (pg/ml) in control females and OCS
users.
Mean ± SE Range
Control females 139.9 ± 27.6 51.1 - 256.2
(n = 8)
OCS users 18.7 ± 0.5* 14.3 - 26.5
(n = 37)
* p < 0.001 when compared to control
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The 24-hour urinary excretion of total estradiol and its individual 
metabolites, free estradiol (E^ ), estradiol glucuronide (E^ G) and 
estradiol sulphate (E^ S) for both control females and OCS users is 
given in Table 5.2
Table 5.2. The 24-hour urinary excretion of estradiol and its
direct conjugates E^G and E^S in control females and 
OCS users (n = 8 and 37 respectively).
Mean ± SE (y g) Range (pig)
CONTROL OCS USER CONTROL OCS USER
Total E^ 4.67 ± 0.97 0.93 ± 0.24** 1.78 - 10.47 0.22 - 6.99
Free E2 0.59 ± 0.35 0.14 ± 0.01* 0.09 - 2.99 0.06 - 0.30
E2G 3.01 ± 0.49 0.53 ± 0.10** 1.24 - 5.49 0.09 - 2.75
E2S ' 1.16 ± 0.23 0.29 ± 0.15** 0.44 - 1.99 0.00 - 4.43
* p < 0.05 when compared to control 
** p < 0.01 when compared to control
The excretion of total estradiol, E^G and E^S were all found to be 
significantly lower in OCS users than in control females (p < 
0.001). The excretion of free estradiol was also lower in OCS users 
than in the control females (p < 0.05).
The relationship between the urinary excretion of free E^ and its 2 
direct phase II metabolites, E^G and E^S in both control females 
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variation in excretion of these 3 compounds, the scattergrams are 
expressed on a log-^ Q scale. A weak positive correlation was found 
between the log^Q urinary excretion of free and E^S (r = 0.352, 
p < 0.05) but a stronger correlation was found between the l°g^Q 
urinary excretion of free E^ and E^G (r = 0.550, p < 0.001).
Further study of these scattergrams show that only 50% of the 
control females excreted elevated amounts of free E^ when compared 
to OCS users, indicating considerable overlap in free E^ excretion 
between the 2 groups. In contrast, 89% of OCS users excreted lower 
amounts of E^G and E^S when compared to control females, indicating 
little overlap in E^G and E^S excretion between the 2 groups.
Fig. 5.4 shows the relationship between the urinary excretion of 
E^G and E^S in both groups and it indicates that there is a 
positive correlation (r = 0.8011, p < 0.001).
The metabolic ratios, free E2/E2G, free E2/E2S and E2G/E2S give an 
indication of the extent to which estradiol undergoes glucuron- 
idation and sulphation and these ratios for both control females 
and OCS users are given in Table 5.3.
The ratio E^/E^t was found to be significantly higher in the 37 OCS 
users when compared to controls (p < 0.05). However, as some of 
the subjects who use OCS were found to excrete no estradiol 
sulphate, they had to be omitted when calculating E2/E2S and 
^2^^2^ s -^nce the ratios would be co .
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Table 5.3.' The ratios E^/E^G, E^/E^S and E^G/E^S in control 
females and OCS users.
Mean ± SE Range
CONTROL OCS USER CONTROL OCS USER
V E2G 0.148±0.058 0.449±0.049* 0.062-0.546 0.052-1.229
W 0.411±0.16 3.38±1.205* 0.115-1.507 0.029-34.00
e2g/e2s 2.833+0.258 10.331±3.38* 2.160-3.89 0.55 - 37.70
* p < 0.05
Therefore, the metabolic ratios E^/E^S and E^G/E^S were found to be 
significantly higher in the 26 OCS users (who had E^S values > 0) 
than the control females (p < 0.05). Figs. 5.5a to c show the 
scattergrams for the metabolic ratios E^/E^G, E^/E^S and E^G/E^S 
and the spread for each of the ratios appears to be much greater 
for the OCS users than the control females. There is little overlap 
between the 2 groups for the metabolic ratios E^/E^G and E^/E^S 
with only 11% of the OCS users having ratios less than those found 
for the majority of the control females. However, the overlap 
appears to be greater for the metabolic ratio E^G/E^S with 30% of 
the OCS users having ratios equal or less than those of the control 
females.
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It is of interest to note that the control female whose values for 
E^ , E^G and E^S excretion were 5 to 10 fold higher than the other 
control females had been subject to deep vein thrombosis which 
required hospital treatment. None of the other control females had 
any personal or family history of thrombosis. In contrast, the few 
OCS users who had elevated values for E^G and E^S excretion in 
comparison to the other OCS users had no distinguishing details to 
account for these differences.
5.4 DISCUSSION
In the present study, the control females were found to have luteal 
phase serum estradiol levels of 139.9 ± 27.6 pg/mi (mean ± SE), and 
they excreted 4.67 ± 0.97 yg of total estradiol in 24 hours.
Similar values have been found by several workers including Brown 
(1960); Knorr et at, (1970) and Fels et at, (1979). The present 
study has also found that OCS users have significantly lower serum 
estradiol levels (18.7 ± 0.5 pg/ml; p < 0.001) together with a 
significantly lower 24-hour urinary excretion of total estradiol 
(0.93 ± 0.24 jig; p < 0.01). However, the sampling times for OCS 
users and the control females are not necessarily equivalent in 
terms of cycle period, which could partially contribute to the 
significant differences in the plasma concentration and urinary 
excretion of estradiol.
The decrease in estradiol concentrations caused by OCS found in the 
present study is supported by several other workers, and this 
effect is due to the activity of the drug. Oral contraceptives act
on the hypothalamus and pituitary gland and prevent ovulation by 
suppressing the mid-cycle increase of LH and FSH levels. However, 
the OCS are also thought to have a direct action on the ovaries. 
Mishell et at, (1972) and Kjeld et at. (1976) have shown that
during OCS use the plasma concentration of estradiol is decreased 
and both the ovulatory peak and the luteal phase rise are uniformly 
suppressed. Similarly, the urinary excretion of total estrogens and 
unconjugated estradiol levels have been found to be significantly 
decreased by OCS use, as reported by Loraine et at, (1965) and 
Kjeld et at, (1976) respectively. Furthermore, the estradiol 
concentrations have been found to remain low during the initial 
cycle of OCS use, and so OCS are thought to have a direct action on 
the ovary whereby estradiol production is decreased. The present 
study has shown that OCS reduce both plasma estradiol and urinary 
total estradiol levels which is to be expected since OCS suppress 
the production of estradiol.
OCS are known to affect the metabolism of many exogenous compounds 
including antipyrine (Abernethy and Greenblatt, 1981), diazepam 
(Abernethy et at,, 1982) and paracetamol (Miners et at,, 1983), but 
little is known about their effect on the metabolism of endogenous 
compounds. Therefore, the urinary excretion of free estradiol and 2 
metabolites, EG and ES was studied. OCS users were found to excrete 
significantly less free E^ ,. E^G and E2S than the control females 
(p < 0.05, p < 0.01, p < 0.01 respectively). However, as a 
significant decrease in estradiol concentrations (both plasma and 
urinary) was found in OCS users compared to control females, 
significant decreases in the urinary excretion of each of the
metabolites is to be expected.
The urinary ratios E^/E^G and E^/E^S provide sin indication of the 
extent of glucuronidation and sulphation of estradiol. The ratio 
E^/E^G was 0.449 - 0.049 in OCS users and 0.148 ± 0.058 in control 
females whilst the ratio E^/E^S was 3.38 ± 1.205 in OCS users and 
0.411 ± 0.160 in control females. Hence both ratios were found to 
be significantly higher in OCS users compared to the control 
females (p < 0.05 for both). The present study has shown that the 
urinary excretion of all 3 metabolites, free E^ , E^G and E^S is 
significantly lowered by OCS use. Therefore, the significant 
increases in the ratios E^/E^G and E^/E^S indicates that the 
excretion of the 3 metabolites are not decreased to the same extent 
by OCS use. The increases in the ratios may be due to:
Either: the decrease in free E^ excretion being comparatively less 
than the decreases in E^G and E^S excretion;
Or: the decreases in E^G and E^S excretion being comparatively 
greater than the decrease in free E^ excretion.
Figures 5.2 and 5.3 indicate that there is little overlap between 
OCS users and control females in the urinary excretion of both E^G 
and E2S, with 87% of OCS users excreting less E^G and E^S than the 
control females. In contrast, these same figures show considerable 
overlap between the 2 female groups in the urinary excretion of 
free estradiol, despite the significant decrease in free E^ 
excretion found in OCS users. Therefore the large overlap found in 
free E^ excretion but not in E^G and E^S excretion may indicate 
that the decrease in free E^ excretion is comparatively less than 
the decrease in E^G and E^S excretion, which may account for the
significant increases in the ratios E^/E^G and E^/E^S found in OCS 
users.
Although a small percentage of estradiol undergoes glucuronide and 
sulphate conjugation, the majority undergoes extensive oxidative 
biotransformation. The oxidative products of estradiol have not 
been studied in the present work; nevertheless, inhibition of one 
or more of the oxidative pathways may result in OCS causing a 
relatively smaller decrease in free E^ excretion compared to the 
decreases in E^G and E^S excretion. This could, in turn, account 
for the significant increases in the ratios E^/E^G and E^/E^S found 
in the present study. The proposal that inhibition of the oxidative 
pathways of estradiol may be ultimately responsible for the 
increase in the metabolic ratios, has support from several workers 
who have examined the effects of OCS on the phase I metabolism of 
numerous exogenous and endogenous compounds. Chronic OCS use has 
been found to impair the metabolic clearance and prolong the 
elimination half-life of many drugs which undergo oxidation. These 
include antipyrine (Abernethy and Greenblatt, 1981); diazepam 
(Abernethy et at., 1982); chlordiazepoxide (Roberts et at., 1979), 
nitrazepam (Jockemsen et at., 1982); caffeine (Patwardhan et at., 
1981) and theophylline (Tomatore et at., 1982).
Furthermore, the effect of chronic OCS use on the metabolism of 
exogenously administered estradiol has been studied (Femino et 
at., 1974). A decrease in the urinary excretion of the 16 
hydroxylated metabolites (namely 16 hydroxyestrone and estriol) 
was found in OCS users together with a decrease in the total 
urinary recovery of the administered estradiol.
These studies have shown that combined OCS impair hepatic 
microsomal oxidation of both exogenous and endogenous compounds. 
This inhibition of phase I metabolism only occurs with OCS 
containing EE^ ; it is not found in mestranol-containing OCS nor in 
progestogen-only preparations. Therefore, it would appear that EE^ 
is responsible for the decrease in oxidation found in OCS users. 
Furthermore, in vitro studies have shown that EE^ treatment 
decreases cytochrome P^q levels and turnover in rats (Mackinnon 
et a l.y 1977).
Hence, the results of these studies indicate that chronic use of 
OCS can result in impairment of phase I metabolism. This supports 
the proposal that the increase in the metabolic ratios E^/E^G and 
E^/E^S found in OCS users may be ultimately due to a decrease in 
the oxidation of estradiol. The oral contraceptives may inhibit 
some oxidation pathways of estradiol (with Femino et al. (1974) 
indicating that 16 hydroxylation is decreased by chronic OCS use) 
resulting in the decrease in free E^ excretion (as caused by OCS 
suppressing estradiol production) being comparatively smaller than 
the decrease in E^G and E^S excretion, which in turn results in 
increased ratios, E^/E^G and E^/E^S.
The metabolic ratio E^G/E^S was found to be significantly increased 
by OCS use in the present study (p < 0.05), which indicates that 
the oral contraceptives cause either an increase in the glucuron- 
idation of estradiol or a decrease in the sulphation. However, OCS 
have been found to produce significant decreases in the urinary
excretion of both E^G and E^ S; although this effect is known to be 
due to the contraceptive activity of the steroids whereby estradiol 
synthesis is maintained at a low level. Therefore, the significant 
increase in the ratio E^G/E^S has to be due "to either a relative 
increase in estradiol glucuronidation in comparison to sulphation, 
or a relative decrease in estradiol sulphation in comparison to 
glucuronidation.
Several workers have studied the effects of OCS use on several 
phase II conjugation reactions. Miners et at. (1983) found that OCS 
use resulted in induction of paracetamol glucuronidation whilst 
paracetamol sulphation was unaffected. A similar result was found 
in the paracetamol population study discussed in Chapter 4. Miners 
et at. (1984), also found that OCS induce glucuronidation of 
clofibric acid. Patwardhan et at. (1981) discovered that the 
clearance of lorazepam and oxazepam was significantly increased in 
OCS users and as the major metabolic pathway of these 2 benzodiaze­
pines is glucuronidation, they proposed that glucuronidation was 
induced during OCS use. Similarly, Ochs et at. (1984) found that 
acetominophen clearance is increased during OCS use and as this 
compound undergoes glucuronidation and sulphation, one or both 
pathways have been induced by OCS use.
Hence these studies show that chronic OCS use can result in 
induction of glucuronidation and to date there is no evidence for 
OCS causing inhibition of any phase II reactions. Therefore, it 
would seem likely that the i-ncrease found in the metabolic ratio, 
E^G/E^S may be due to induction of estradiol glucuronidation rather 
than inhibition of estradiol sulphation. Thus as OCS are known to
cause induction in the glucuronidation of several exogenous 
compounds including paracetamol, clofibric acid, lorazepam, 
oxazepam and acetominophen, they may also increase the glucuron­
idation of the endogenous compound, estradiol. The relative 
increase in E^G excretion in comparison to E£S excretion as found 
in the present study indicates that glucuronide induction may have 
occurred but further work must be done to confirm this.
Chronic OCS use may result in induction of estradiol 
glucuronidation, but the metabolic ratio E^/E^G was found to be 
increased in OCS users and not decreased as would be expected if 
the excretion of E^G was elevated in these subjects. This 
discrepancy is probably due to only a small percentage of estradiol 
undergoing direct conjugation with glucuronide and sulphate. The 
majority of estradiol undergoes oxidative biotransformation prior 
to conjugation and subsequent urinary excretion. Consequently, if 
OCS do cause inhibition of some of the oxidative pathways the 
resultant increase in free E^ levels may be greater than the 
inductive effect of these steroids on the glucuronidation pathway 
causing a decrease in free E^ levels, as oxidation is the major 
metabolic biotransformation of estradiol whilst direct conjugation 
is relatively minor.
CHAPTER SIX
THE EFFECT OF CHRONIC ETHINYLESTRADIOL PRETREATMENT 
ON PARACETAMOL AND ESTRADIOL METABOLISM IN THE FEMALE RAT
6.1 INTRODUCTION
Chronic use of oral contraceptive steroids (OCS) has been shown to 
increase paracetamol clearance, due to induction of both the 
glucuronidation and oxidation pathways but no change in the 
sulphation pathway was reported (Miners et at,, 1983). Similarly, 
chronic OCS use has been found to increase the clearance of 
exogenously administered estradiol (Longscope and Williams, 1974; 
Slikker et at. 3 1984), which Slikker et at. have indicated is due 
to induction of the ‘estradiol metabolites, estrone and estrone 
glucuronide formation. However, the component of the OCS that is 
responsible for this induction is not known. Therefore, the effect 
of the estrogenic element, ethinylestradiol (EE^ ), on the 
metabolism of paracetamol and estradiol in the female rat was 
studied with a view to obtaining the effect of EE^ on exogenous and 
endogenous metabolism.
6.2 PROCEDURES
Female Wistar rats weighing 200 to 220 g were used for the studies; 
n = 24 for the paracetamol study and n = 17 for the estradiol 
study. All of the rats were treated orally for 40 days; half of the 
rats receiving 1 ml of 5% ethanol (control rats) and the- other half 
receiving 1 ml of EE^ solution (11 yg EE^/ml in 5% ethanol; test
150.
rats).
For the paracetamol study on day 29 of dosing, all 24 rats received 
a single oral dose of paracetamol (50 mg/kg) and urine was 
collected from 0 - 8  and 8 - 2 4  hours. On day 40 a second oral dose 
of paracetamol (50 mg/kg) was administered and the animals were 
bled by cardiac puncture over 8 hours at 10, 15, 30, 45, 60, 90,
120, 180, 210, 240, 360 and 480 minutes. Each animal was bled up to
4 times, with a maximum of 2 mis of blood taken on each occasion. 
Each bleed was followed by a 2 ml subcutaneous injection of 0.9% 
NaCl. Paracetamol (P), paracetamol glucuronide (PG) and paracetamol 
sulphate (PS) were analysed in the urine by HPLC together with 
paracetamol in serum as described in 2.8a and b.
For the estradiol study on day 40, 3 of the control rats and 4 of
14the test rats were cannuiated and C-170-estradiol (26.6 Mg E^ ;
5.075 MCi/kg) was administered through the jugular vein and the
animals were bled from the carotid artery over 3 hours at 1, 2, 4,
6, 8, 10, 13, 16, 20, 30, 45, 60, 90, 120, 150, 180, 210 and 240
minutes. Each animal had up to 7 blood samples taken, with a
maximum of 0.5 ml of blood taken on each occasion. The remaining 
14rats had C-176-estradiol injected into the tail vein, also on day 
40 and the urine and faeces were collected for 24 hours. At the end 
of the 24 hour urine collection, the animal was sacrificed and the 
liver, kidney and the small and large intestine were removed. The 
radioactivity in the serum, urine, faeces and tissues was 
determined using the liquid scintillation counter as described in 
2.1.




The effects of chronic EE^ pretreatment on the urinary excretion of 
paracetamol and its major metabolites PG and PS in the rat are 
shown in Figs. 6.1 to 6.4, and Table 6.1.
The EE^-treated rats were found to excrete more PG in 0 to 8 hours 
than the control rats (p < 0.05) with P and PS excretion being 
similar in both groups. Furthermore, the total dose recovered in 
the 0 - 8  hour urine was found to be in the EE^-treated rats
but this difference failed to reach significance. In the 8 to 24 
hour urine collection, EE^-treated rats excreted significantly less 
PS than control rats (p < 0.05) but P and PG excretion showed no 
difference between the 2 groups. The total dose recovered in this 
time period was significantly " in EE^-treated rats
(p < 0.05) than in non-treated rats. The EE^-treated rats were 
found to excrete more PG and less PS than the control rats in the 0 
to 24 hour urine, but these differences failed to reach 
significance. Total recovery in this time period, together with the 
free P excretion were similar in both groups.
Table 6.2 and Figs. 6.5a and b show the effects of chronic EE^ 
pretreatment on the serum clearance of paracetamol.
Table 6.1. The urinary excretion of P, PG and PS in control and test rats. (Results expressed as % 
of dose recovered; mean - SE).
0-8 hours
CONTROL 
8-24 hours 0-24 hours 0-8 hours
TEST 
8-24 hours 0-24 hours
p 1.8 ± 0.1 1.3 ± 0.3 3.1 ± 0.3 2.0 ± 0.2 1.1 ± 0.3 3.0 ± 0.4
PG 11.1 ± 1.1 2.7 ± 0.5 14.0 ± 1.0 16.0 ± 1.7* 2.8 ± 0.6 18.2 ± 1.8
PS 40.9 ± 3.5 19.1 ± 2.2 ' 60.0 ± 3.0 45.1 ± 3.5 12.3 ± 1.8* 55.6 ± 3.5
P+PG+PS 53.9 ± 4.4 23.2 ± 2.4 77.1 ± 3.6 63.1 ± 5.2 16.3 ± 2.3* 76.9 ± 5.3
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Serum paracetamol clearance from 0 to 8 hours
(Mean ± SE)
PARACETAMOL IN SERUM 
TEST -
12.0 ± 0.9





3.0 ± 0.4 
1.95 ± 0.13 
0.48 ± 0.03 
0.76 ± 0.06 
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The mean serum paracetamol concentration was found to be lower in
the EE^-treated rats than the control rats at all time points, the
difference becoming greater after 3 hours. However, possibly due to
the interanimal variation and the small number of animals used per
time point, these differences in serum concentration failed to
reach significance. The area under the time-concentration curve
(AUC) appeared to be lower in the treated animals. Furthermore, the
elimination half-life (tv$) also appeared to be lower in the test
' 2
rats, although similar values were obtained for the initial
half-life (tva) for both the test and control rats.
'2
b) Discussion
The present study has shown that chronic pretreatment with EE^
results in a significant increase in the 0 to 8 hour urinary
excretion of PG, suggesting that the glucuronidation pathway has
been induced. As PG is not the major metabolite of paracetamol in
the rat the total dose recovered was not significantly altered by
EE^ pretreatment. However, both the g and the half-life,
tv0, appeared to be lower in the EE -treated rats which suggests 
'2 <-
that the serum clearance of paracetamol may be increased by EE^ 
pretreatment. Therefore, the inductive effect of EE^ on paracetamol 
glucuronidation found in the rat may be sufficient to cause an 
apparent increase in paracetamol serum clearance, together with an 
apparent decrease in paracetamol half-life.
Combined OCS containing EE^ have been found to cause induction of 
the glucuronide pathways in females using this form of hormonal
contraception. Drugs such as paracetamol, clofibric acid (Miners 
et at., 1983, 1984, rspectively); lorazepam and oxazepam 
(Patwardhan et at., 1981) have been reported to show induction of 
glucuronidation in chronic OCS users. Similarly the present study 
has indicated that OCS use results in am increase in PG excretion 
as discussed in Chapter 4. The findings of the present rat study 
suggests that it is the EE^ component of the OCS which is 
responsible for the induction of glucuronidation found in the 
several human studies reported earlier.
In contrast, Hargreaves et at. (1971) found that EE^ reduced the 
glucuronide conjugation of bilirubin and o-aminophenol when 
studied in vitro. However, Watanabe (1970) reported that pre­
treatment with EE^ resulted in a decreased bile flow (p < 0.001) 
and Hiekel and Lathe (1970) found that OCS caused a decrease in 
bilirubin excretion. Therefore, the results of Hargreaves et at. 
may be due to a decrease in bilirubin excretion rather than a 
decrease in bilirubin conjugation. Furthermore, the study of 
Hargreaves et at. was performed in vitro using rat liver slices and 
no pretreatment with EE^ occurred. Hence, the results found are not 
directly comparable with the present study where the rats were pre­
treated for up to 40 days in an attempt to mirror the normal 
clinical situation of OCS use.
Although in the present study, EE^ pretreatment was found to cause 
induction of paracetamol glucuronidation, a delayed inhibition of 
paracetamol sulphation was also found. In the 8 - 2 4  hour urine, 
significantly less PS was excreted, and as this is the major 
metabolite in the rat, this resulted in a significant decrease in
the percentage recovery of the drug in this time period. If the 
glucuronidation and sulphation pathways of paracetamol were in 
competition with each other, as found in the human paracetamol 
study as discussed in Chapter 4, the induction of paracetamol 
glucuronidation could account for the decrease in paracetamol 
sulphation. However, the delayed decrease in PS excretion could 
also be due to depletion of available sulphate as both EE^ and 
paracetamol undergo sulphate conjugation and so may be in 
competition with each other for the supplies of sulphate. 
Furthermore, the 2 compounds may be in direct competition for the 
enzyme sulphotransferase, and as the concentration of paracetamol 
becomes progressively lower, EE^ may competitively inhibit the 
sulphation of paracetamol. No work has been published to date on 
the effect of EE^ on sulphate conjugation, and so further studies 




Tabie 6.3 and Fig. 6.6 show the serum concentrations of estradiol
for both control rats and the EE^-treated rats. From 1 to 16
minutes the serum estradiol concentrations were found to be higher
in the control rats than in the test rats; however, from 20 to 120
minutes the reverse was true, estradiol concentrations were higher
in the test rats than in the control animals. Possibly due to the
large inter-animal variation and the small number of animals used
per time point, these differences failed to reach significance.
The area under the time-concentration curve (AUC- 1C<~) was similar
1—1 bu
3 3in both test and control rats (30.04x10 and 29.02 x 10 DPM/o.l ml
min respectively). Also the initial half-life (tva) and the
A2
elimination half-life (tv 3) appeared to be similar in both animal
'Z
groups, with the control rats having half-lives of 6.1 and 53.7 min 
and the test rats having half-lives of 5.4 and 49.5 min.
The 24-hour urinary excretion of estradiol, together with the 
tissue content of administered estradiol for both control and 
treated rats is given in Table 6.4 and Figs. 6.7 to 6.9.
The 24-hour urinary excretion of total estradiol was found to be 
significantly higher in the EE^-treated rats than in the control 
animals (p <0.01) whilst the radioactive content of the liver was 
also apparently lower in EE^-treated rats, but possibly due to the 
inter-animal variation this difference failed to reach significance 
(p < 0.1). Similarly, the radioactivity found in the large
Table 6.3. Serum estradiol clearance from 0 to 3 hours 
(Mean ± SE)
t o t a l
Serum concentration of^estradiol (DPM/0.1 ml)
TIME
(minutes) CONTROL TEST
1 1117.8 1074.5 ± 205.2
2 963.1 ±42.1 757.95± 163.0
4 666.75± 97.2 644.5 ± 120.3
6 588.1 ± 65.8 605.0
8 572.0 ± 96.5 489.6 ± 55.6
10 495.4 ± 41.3 472.4 ± 34.1
13 432.5 ±29.75 412.6 ± 36.7
16 426.3 ± 34.1 389.6 ±9.6
20 308.6 ± 24.9 396.2 ± 17.7
30 287.8 ± 21.2 299.9 ± 25.4
. 45 212.4± 24.4 320.2 ± 68.0
60 137.3 ± 9.7 170.25± 12.2
90 98.5 ± 19.25 101.8
120 88.5 ± 7.3 115.25
180 54.0 ± 8.0
AUC 29.02 x 103 DPM/0.1 ml 30.04 x 103 DPM/0.1
5.1 min 5.4 min
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Table 6.4. The 24-hr urinary and tissue estradiol content in 
test and control rats (mean - SE)
TISSUE
ESTRADIOL CONTENT (CPM (xl03)/g tissue) 
TEST (n=5) CONTROL (n=5)
Liver 2.31 + 0.28 2.84 ± 0.14
Small intestine (SI) 28.66 + 4.20* 62.28 ± 14.28
Large intestine (LI) 86.66 + 14.07 116.10 ± 14.63
Faeces 158.86 + 92.98 39.33 ± 18.32
Faeces + LI 103.61 + 17.28 105.21 ± 10.81
Faeces + LI + SI 68.82 + 7.80 84.85 ± 4.90
Urine 33.77 + 2.38* 19.69 ± 1.02
CPM CPM
* p < 0.01 compared to control.
intestine and the faeces showed no significant difference between 
the test and control rats (p < 0.1). However, the radioactive 
content of the small intestine after 24 hours was found to be 
significantly lower in the test rats (p < 0.01).
b) Discussion
The chronic administration of to female rats resulted in slight 
apparent differences in the-serum concentrations of estradiol. 
However these apparent differences were not reflected in the 
pharmacokinetic variables, area under the time-concentration curve 
(AUC) and the half-lives. The AUC together with the initial and
elimination half-lives for both test and control rats were similar 
indicating a similar serum clearance for estradiol in the 2 animal 
groups. Hence chronic treatment with EE^ appears to have no effect 
upon the initial ( 0 - 3  hour) clearance of estradiol. This is in 
contrast to the results obtained by Slikker et at. (1983), where 
chronic use of a combined oral contraceptive containing ethynerone 
and mestranol was found to significantly increase estradiol 
clearance from 0 - 6  hours. This discrepancy could be due to 
species differences as Slikker et at. used monkeys whereas rats 
were used in the present study. Furthermore, Slikker et at. 
administered a progestin, ethynerone, and the estrogen mestranol, 
whereas the estrogen, ethinylestradiol alone was administered in 
the present work. Also the time period used by Slikker et at. to 
determine estradiol clearance was double that used in the present 
study.
Although chronic EE^ pretreatment was found to have no effect upon 
the 0 to 3 hour serum clearance of estradiol, the 24-hour urinary 
excretion of estradiol was significantly increased in the 
EE^-treated rats (p < 0.01). As estradiol is subject to 
enterohepatic circulation, the estradiol content of the liver, 
small intestine, large intestine and faeces, 24 hours after 
administration were also studied. The liver appeared to have a 
lower estradiol content in the treated rats when compared to the 
control group, but possibly due to the interanimal variation, this 
failed to reach significance. The estradiol content of the faeces 
and the large intestine showed no significant difference between 
the 2 groups but the estradiol content of the small intestine was 
significantly lower in the EE^-treated rats. Thus the present study
has shown that chronic use of EE^ in female rats significantly
increases the 24-hour urinary excretion of estradiol whilst there
was significant lowering of the estradiol content of the small
14intestine determined 24 hours after C-estradiol administration. 
These results suggest that the increase in the urinary output of 
estradiol may be due to the decrease in the intestinal content. 
Furthermore, the decreased estradiol content of the small intestine 
indicates that EE^ has some effect upon the enterohepatic 
circulation of estradiol.
Chronic pretreatment of rats with EE^ at doses of 0.5 to 1.0 mg/kg 
for 5 to 9 days has been shown to decrease bile flow and biliary 
excretion (Heikel and Lathe, 1970; Kreek et at. » 1969; Watanabe, 
1971). Similarly acute treatment with the glucuronide conjugate of 
EE2 has also been found to decrease bile flow (Vore et at. y 1983). 
Therefore the reduction in bile flow caused by EE2 may result in 
decreased biliary excretion of estradiol and so could account for 
the decreased estradiol content of the small intestine found in the 
EE^-treated rats of the present study.
Furthermore, if bile flow was decreased, resulting in decreased 
biliary excretion of estradiol, this would result in increased 
concentrations of estradiol leaving the liver. However only 
approximately 2% of the administered dose undergoes biliary 
excretion as free estradiol; the remainder is excreted into the 
bile as glucuronide conjugates, the major metabolites being the 
glucuronide conjugates of 2-methoxyestrone and 2-hydroxyestrone 
(Watanabe, 1970). Thus, the decreased bile flow causes a decrease
in the biliary excretion of the glucuronide conjugates. This 
results in the concentration of the estradiol glucuronides leaving 
the liver being raised and as these compounds are highly 
water-soluble, they are readily excreted in the urine.
The increased urinary excretion of estradiol, found in EE^-treated 
rats may be due to decreased enterohepatic circulation of 
estradiol, as indicated by the lowered total estradiol content of 
the small intestine. In addition the increased urinary excretion of 
estradiol may also be due to induction of estradiol metabolism. 
Chronic use of EE^ has been shown to induce paracetamol glucuron­
idation in female rats (Chapter 6.3) and so it may also cause 
induction of the glucuronidation of estradiol. Following chronic 
administration of combined OCS to monkeys, Slikker et at.a (1984), 
found that the clearance of exogenously administered estradiol was 
significantly increased in the treated animals, which they 
attributed to the increased urinary excretion of estrone and 
estrone glucuronide. Therefore, Slikker et at. stated that the OCS 
used caused induction of estradiol metabolism namely the biotrans­
formation to estrone and the glucuronidation pathway. Hence, 
combined OCS use has been shown to induce estradiol metabolism in 
morkeys and the present study indicates that EE^ pretreatment may 
also result in induction of estradiol metabolism.
CHAPTER SEVEN 
COMPARISON OF FACTORS AFFECTING GLYCINE, GLUCURONIDE 
AND SULPHATE CONJUGATION
7.1 GENETIC CONTROL OF DRUG METABOLISM
Population studies involving the administration of a probe drug and 
the determination of its metabolic profile are widely used in order 
to examine the genetic control of various metabolic biotransform­
ations. One of the earliest examples of this form of pharmaco- 
genetic study was performed by Evans et at. (1960), whereby the 
8-hour urinary excretion of N-acetyl isoniazid, the major 
metabolite of the probe drug isoniazid, was determined in a large 
number of subjects. A bimodal distribution was found, indicating 
that N-acetylation of isoniazid is subject to genetic control with 
approx. 38% of the UK population studied being slow acetylators. 
Family studies were then performed and slow acetylation was found 
to be an autosomal recessive trait. Other compounds which also 
undergo acetylation have been found to be subject to genetic 
control; these included dapsone, hydralazine, procainamide, 
phenelzine, nitrazepam and certain sulphonamides (for references 
see Lunde et at. (1977)).
A significant progress was made in the field of pharmacogenetics 
during the 1970's when Mahgoub et at. (1977) discovered monogenic 
control of oxidation. The approach was similar to that used by 
Evans et at, and involved the determination of the 0 - 8 hr urinary 
excretion of the probe drug debrisoquine and its major metabolite
4-hydroxydebrisoquine. The metabolic ratio between debrisoquine and 
4-hydroxydebrisoquine gave a bimodal distribution with approx­
imately 3% of the population studied being poor metabolisers and 
family studies showing that the poor oxidiser phenotype is 
controlled by an autosomal recessive gene. At least 22 other drugs 
which utilise the same hepatic drug oxidising pathway as debriso­
quine have been found to be subject to genetic control including 
sparteine (Eichelbaum et at., 1979); phenytoin (Sloan et at.,
1981); certain B-blockers (Dayer et at., 1985); guanoxan and 
phenacetin (Sloan et at., 1978).
Oxidation is the major phase I metabolic pathway and as a result 
numerous pharmacogenetic studies have been and still are being 
performed for the wide range of drugs which undergo this biotrans­
formation. However, acetylation is only one out of the 8 phase II 
metabolic reactions which are known to occur in maui. Very few 
pharmacogenetic studies have been performed on the other 7 
conjugation pathways. Therefore in the present work, population 
studies were carried out to determine whether glycine, glucuronide 
and sulphate conjugation were subject to genetic control using 
aspirin and paracetamol as the probe drugs. The 0 - 8  hour urinary 
excretion of salicylic acid (SA) and its major metabolite, the 
glycine conjugate, salicyluric acid (SUA) was determined in 150 
healthy volunteers following an oral therapeutic dose of aspirin 
(600 mg). Similarly, the 0 - 8  hour urinary excretion of para­
cetamol (P) and its major metabolites, paracetamol glucuronide (PG) 
and paracetamol sulphate (PS) was determined in 99 healthy
volunteers following an oral therapeutic dose of paracetamol (1 g). 
In the population study for aspirin discussed in Chapter 3, the 
metabolic ratio between SA and its major metabolite, SUA, showed a 
skewed distribution. However, together with the large interindivi­
dual variation found for the metabolic ratio SA/SUA a large intra 
individual variation was also found. The skewed distribution 
indicates that there may be genetic control of the glycine 
conjugation of SA, however as the distribution was not multi-modal 
and no separate phenotypes could be distinguished, environmental 
factors may have a large influence on salicylate metabolism. 
Furthermore the large intraindividual variation of the salicylate 
metabolic ratio shows that environmental factors probably do have a 
greater influence on the glycine conjugation of SA than genetic 
factors. In the population study for paracetamol discussed in 
Chapter 4, the metabolic ratios between P and PG and between P and 
PS both showed unimodal distributions, indicating that the 
glucuronide and sulphate conjugation of paracetamol are subject to 
polygenic and multifactorial control. In contrast, the large 
numbers of drugs which undergo oxidation and acetylation both show 
bimodal distributions with 2 distinct phenotypes, together with 
small intraindividual variations, indicating strong monogenic 
control with environmental factors having only a comparatively weak 
effect on these 2 metabolic pathways.
Genetic control of phase I metabolism has been extensively studied 
and a large number of drugs which undergo oxidation have been found 
to be subject to monogenic control. However, although phase II
metabolism is responsible for terminating the activity of many 
exogenous and endogenous compounds, the study of genetic control in 
conjugation reactions has been limited to acetylation, which is 
also known to be under monogenic control. Therefore, the present 
work was undertaken to extend the knowledge of genetic control of 
phase II metabolism. The population study for paracetamol provided 
no evidence for the genetic control of sulphate and glucuronide 
conjugation whilst the population study for aspirin showed glycine 
conjugation may be subject to weak genetic control, but environ­
mental factors have a far greater influence. Hence, three of the 
major phase II reactions; glycine, glucuronide and sulphate 
conjugation are not subject to genetic control.
7.2 ENVIRONMENTAL CONTROL OF PHASE II METABOLISM 
a) Age
The present work has shown that age has no effect upon the glycine 
conjugation of SA nor upon the glucuronide and sulphate conjugation 
of paracetamol in the age ranges studied of 18 to 61, years and 18 
to 62 years respectively. Conversely, other workers have found that 
the renal clearance of SUA decreases with increasing age (e.g.
Ho et at., 1985) and paracetamol plasma clearance has been found by 
several workers to be significantly decreased in elderly subjects 
(e.g. Triggs et at., 1975). The contrasting results obtained from 
these studies compared to those of the present work are probably 
due to the limited age range of the latter, for both Ho et at. and 
Triggs et at. included subjects aged over 65 years whilst the 
studies discussed in Chapters 3 and 4 had a maximum age of 61 and 
62 years respectively. Therefore, in order to detect any effect of 
age upon drug metabolism, subjects aged 65 or over must be included 
in the study.
Although it was not found in the present work due to the limited 
age range used, other workers have shown that old age (i.e. 65 
years or over) appears to decrease the capacity for the phase II 
metabolic pathways; glycine, glucuronide and sulphate conjugation. 
The major phase I metabolic pathway, hepatic oxidation, has also 
been found to be significantly lowered in elderly subjects (Crooks 
and Stevenson, 1977). Hence it would seem that aspects of both 
phase I and phase II metabolism are impaired in elderly subjects 
aged over 65 years.
b) Gender
The aspirin study discussed in Chapter 3 showed that females 
excreted significantly less SUA and significantly more SA than 
males following aspirin administration. Several workers have also 
reported that the plasma clearance of salicylate is significantly 
decreased in females (Ho et at., 1985; Miners et at,, 1986) which, 
as the present work has shown, is due to a decreased capacity for 
glycine conjugation.
The paracetamol study discussed in Chapter 4 showed no sex diff­
erences in the urinary excretion of P, PG and PS. This is in 
contrast to other workers who have found decreased paracetamol 
plasma clearance in females, accompanied by a decreased renal and 
metabolic clearance of PG (Miners et at., 1983), which indicates a 
decreased capacity for glucuronide conjugation in females. However, 
as no sex differences were found in paracetamol metabolism in the 
present work, which involved a large number of volunteers, the 
decreased paracetamol clearance found in females by other workers, 
which involved a comparatively small number of volunteers, may be 
of little clinical significance.
Recent studies have shown sex differences in oxidative metabolism 
with female rats showing pronounced decreased clearance of a number 
of drugs which undergo oxidation (Kato, 1974). Similarly, studies 
in man have shown that females have a decreased oxidative capacity 
compared to males, as indicated by the decreased clearance of drugs 
such as diazepam (Geenblatt et at., 1980) and chlordiazepoxide 
(Roberts et at., 1980) found in females. Thus, the phase I 
metabolic reaction, oxidation, and the phase II reactions, glycine
and possibly glucuronide conjugations, have been shown to be sex 
dependent, with females having a reduced capacity for these 
pathways, whilst sulphate conjugation appears to show no sex 
differences.
c) Smoking
Smoking was found to have no effect upon the glycine conjugation of 
SA, nor upon the sulphate conjugation of paracetamol in the present 
work. However, the glucuronide conjugation of paracetamol was found 
to be significantly increased by smoking, although this effect was 
found in females only.
Cigarette smoke contains polycyclic hydrocarbons (Wynde and 
Hoffman, 1950) which are known to be potent enzyme inducers. The 
activity of several hepatic microsomal enzyme systems is increased 
by these compounds including N-demethylation, hydroxylation, 
reduction and glucuronide conjugation (Conney and Burns, 1962), 
although considerable substrate specificity is exhibited.
The enzyme systems subject to induction by polycyclic hydrocarbons 
are believed to be situated in the hepatic microsomes (Conney and 
Burns, 1962) and both glycine and sulphate conjugation are non- 
microsomal (glycine conjugation occurring in the hepatic mito­
chondria and sulphation occurring in the kidney, intestinal mucosa 
and the soluble fraction of the hepatic cell). Therefore, it is to 
be expected that these 2 metabolic pathways are not affected by 
cigarette smoking. Conversely, glucuronidation is a hepatic 
microsomal pathway, and the results of the present study indicate 
that paracetamol is a suitable substrate for induction by the
polycyclic hydrocarbons present in cigarette smoke. Hence it would 
appear that cigarette smoke induces a variety of phase I metabolic 
reactions, but glucuronidation may be the only phase II reaction 
which it is known to induce.
d) Oral Contraceptive Steroids
In the present work, oral contraceptive steroids were found to have 
no effect upon the glycine conjugation of salicylate. This is in 
contrast to the results of other studies performed in small groups 
of subjects where the plasma clearance of salicylate was found to 
be increased in OCS users (Gupta et at., 1982; Miners et at., 1986) 
indicating an increased glycine conjugation in these subjects. 
However, due to the small number of subjects used and the near 
basal conditions employed, this induction may be of little clinical 
significance.
The glucuronidation of paracetamol was found to be increased in OCS 
users in the present study, although this difference failed to 
reach significance whereas the sulphation of paracetamol was found 
to be significantly decreased by OCS use. As glucuronidation and 
sulphation of paracetamol have been shown to be in competition with 
each other (see Chapter 4), a decrease in one pathway will result 
in an increase in the competing pathway and vice versa, and so the 
increase in glucuronidation found in OCS users may be the cause of 
the decrease in sulphation.
Several other workers have found paracetamol plasma clearance to be 
decreased by OCS use (Miners et at., 1983; Mitchell et at., 1983). 
This increase in paracetamol clearance was reported to be due to
induction of the glucuronidation pathway with the OCS having no 
effect upon the sulphate conjugation.
The estradiol study discussed in Chapter 5 found significant 
increases in the urinary metabolic ratios E^/E^G and E^/E^S in the 
subjects using OCS, which indicated that OCS may decrease the 
oxidation of estradiol. This result is supported by a study 
performed by Femino et al. (1974), which stated that OCS use 
decreased the urinary excretion of the 16 -hydroxylated metabolites 
of exogenously administered estradiol. Furthermore, numerous other 
compounds which undergo oxidation, have also shown a decreased 
plasma clearance in OCS users, including antipyrine (Abernethy and 
Greenblatt, 1981); chlordiazepoxide (Roberts et at,, 1979) and 
caffeine (Patwardhan et al., 1981).
In addition to the possible effects on the oxidation pathway, the 
estradiol study of the present work has also shown a significant 
increase in the metabolic ratio E^/E^S in OCS users, indicating 
either a possible increase in estradiol glucuronidation or a 
possible decrease in estradiol sulphation. Several workers have 
found that OCS use results in induction of glucuronidation of 
several drugs including paracetamol and clofibric acid (Miners 
et al. > 1983, 1984); lorazepam and oxazepam (Patwardhan et al., 
1981). No reports have been published on OCS causing decreased 
sulphation, apart from the paracetamol study discussed in Chapter 
3, where glucuronidation and sulphation were competing pathways. 
Hence chronic OCS use may cause induction of endogenous estradiol 
glucuronidation rather than inhibition of estradiol sulphation.
181 .
Animal Studies: Effect of EE  ^on Phase II Metabolism 
The chronic pretreatment of EE^ in female rats as discussed in 
Chapter 6, has been found significantly to increase the 0 - 8  hour PG 
urinary excretion followed by a delayed significant decrease in the 
8 - 2 4  hour urinary excretion of PS. An apparent increase in 
paracetamol plasma clearance was also obtained in the EE^-treated 
rats, although this difference failed to reach significance. Hence, 
chronic administration of EE^ appears to cause induction of the 
glucuronidation pathway which may be responsible for the apparent 
increased plasma clearance. The decrease in PS excretion observed 
in EE^-treated rats may be either due to competition between EE^ 
and paracetamol for the sulphotransferase enzyme or the available 
supply of sulphate. An alternative explanation may be that 
sulphation and glucuronidation of paracetamol may be in competition 
with each other as found in man (see Chapter 4) and so an increase 
in PG excretion will result in a subsequent decrease in PS 
excretion.
The induction of the glucuronidation pathway of paracetamol due to 
EE^ pretreatment, mirrors the situation found in man due to OCS 
use. Hence the estrogenic component of the OCS may be responsible 
for this induction although the studies performed in man and the 
rat study discussed in Chapter 5 are not directly comparable. This 
is due to the rats receiving a much larger daily dose of EE^ (11 Jig 
per day) on a mg/kg basis, than the daily dose of EE2 taken during 
combined OCS use (30 or 50yg per day) by females. Large doses of EE2 
were given to the rats in order to determine whether EE2 pretreat­
ment could competitively inhibit the conjugation of paracetamol, as
both compounds undergo glucuronide and sulphate conjugation.
The present work has indicated that it is the estrogenic component 
of combined OCS which causes induction of glucuronide conjugation. 
Therefore, if a female using combined OCS (containing EE^) takes 
another drug concomitantly, which is inactivated by glucuronid­
ation, the plasma clearance of the second drug may be increased, 
resulting in a decreased activity of that drug.
The effect of chronic EE^ pretreatment on estradiol metabolism was 
also determined using female rats. The 0 - 2 4  hour urinary excre­
tion of total estradiol was found to be significantly increased by 
EE^ pretreatment, whilst the small intestine content of total 
estradiol was found to be significantly lowered. Therefore, it was 
suggested that the increased urinary excretion of total estradiol 
may be due to decreased enterohepatic circulation. OCS have been 
found to reduce the bile flow and decrease biliary excretion 
(Heikel and Lathe, 1970; Kreek et al. 3 1969) and as conjugates of 
estradiol and conjugates of its phase I metabolites, estrone and 
estriol, are excreted into the bile, a decrease in bile flow will 
result in a subsequent decrease in the biliary excretion of the 
estrogen conjugates. Hence decreased biliary excretion of the 
estrogen metabolites could account for the increased urinary 
excretion of total estradiol. Furthermore, EE^ may be causing 
induction of the glucuronidation pathway, as was found in the 
paracetamol rat study (see Chapter 6.3). This induction will 
further enhance the increased urinary excretion of total estradiol. 
The present work has indicated that chronic OCS use in females may 
induce the glucuronidation of estradiol (see Chapter 5), and the
increased urinary excretion of estradiol found in the present rat 
study, has shown that EE^ may contribute to this induction.
However, as the urinary excretion of the estradiol metabolites was 
not studied direct induction of the glucuronide pathway cannot be 
surmized. The impairment of estradiol oxidation which may have 
occurred in OCS users (see Chapter 5) was not discovered during 
chronic EE2 pretreatment in female rats. This may have been due to 
the limitations of the study where changes in the phase I meta­
bolism of estradiol would not be detected, or the oxidation of 
estradiol may not have been affected by EE^ pretreatment. Further 
work needs to be performed in order to determine which component is 
responsible for decreasing oxidation of both exogenous and 
endogenous compounds.
Summary of the Effects of Oral Contraceptive Steroids 
The present work has found that OCS'use may result in either 
induction of the glucuronidation of paracetamol and endogenous 
estradiol or inhibition of the sulphation pathways of these 2 
compounds. However, evidence from other workers indicates that 
induction of the glucuronidation pathway is more likely.
Glycine conjugation was not found to be affected by OCS use, 
indicating that the contrasting results of other workers may be of 
little clinical significance. OCS use may also result in the 
inhibition of endogenous estradiol oxidation, which supports the 
results of other workers who found that OCS cause inhibition of the 
oxidation of several compounds, including exogenously administered 
estradiol.
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APPENDIX 1. Details of volunteers in aspirin study and the total amounts of aspirin metabolite excreted in a 0 - 8 hr urine 















Amount recovered in 0-8 
urine (mg) 
Observed SA corrected 





1 F 24 44 No 745 6.70 29.2 20.4 201.2 0.101
2 M 24 70 Yes - 885 6.27 5.3 4.3 200.9 0.021
3 M 18 63 N/K - 400 6.93 31.4 17.0 217.9 0.078
4 M 19 70 N/K - 415 7.00 26.5 10.1 201.6 0.050
5 M 24 71 No - 320 5.92 11.3 14.7 233.1 0.063
6 M 29 65 No - 555 6.43 13.2 9.7 193.4 0.050
7 F 21 63 No ocs 270 5.70 5.7 11.1 226.1 0.049
8 M 18 73 N/K . - 845 6.12 8.9 10.0 236.3 0.042
9 M 20 67 No - 270 6.90 14.8 1.2 226.0 0.005
10 F 20 N/K No - 685 6.47 24.8 20.6 199.6 0.103
11 F 20 68 N/K N/K 570 6.40 17.0 14.0 179.3 0.078
12 M 18 64 N/K - 410 5.95 10.9 13.9 171.6 0.081
13 M 19 N/K N/K - 360 5.30 2.9 10.9 229.9 0.047
14 M 22 60 N/K - 400 6.80 37.1 26.0 211.6 0.123
15 M 18 76 N/K - 965 7.00 19.7 3.3 199.6 0.016
16 F 19 54 N/K N/K 600 6.15 15.15 15.85 203.7 0.078
17 F 20 58 N/K N/K 645 7.00 40.4 24.0 95.0 0.253
























Body Other drugs taken Urine Urine Amount recovered in 0-8 hr
Weight Smoker concomitantly Volume pH urine (mg)
(kg) with aspirin (mis) Observed SA corrected SUA
SA to pH 6.2
73 No - 1090 6.70 13.2 4.4 158.4
68 No - 375 6.40 20.5 17.5 235.8
67 No - 895 6.30 9.5 8.1 211.8
54 N/K N/K 305 5.35 5.4 13.2 144.8
60 No - 605 6.07 10.6 12.3 192.4
57 No - 710 7.30 86.1 59.9 96.0
70 N/K - 345 6.15 14.0 14.7 205.6
57 No - 850 6.10 14.3 15.6 209.3
76 No - 355 6.43 16.95 13.45 210.6
70 No - 625 6.47 9.0 4.8 183.4
63 No - 295 6.03 22.7 24.9 220.6
60 No - 1055 6.70 19.25 10.45 224.8
57 No ocs 595 5.95 13.6 16.6 164.0
60 N/K N/K 155 5.97 3.8 6.6 206.3
90 N/K N/K 280 6.00 12.9 15.4 237.4
64 N/K N/K 230 7.00 19.9 18.9 211.1
95 N/K - 390 6.00 15.15 17.6 255.4
68 N/K - 895 6.50 20.3 15.5 153.8
76 No - 1830 6.35 32.7 30.5 218.6
70 No Oxytetracycline 310 5.23 1.1 9.5 197.0
67 No - 400 5.27 3.0 11.2 269.0
















Amount recovered in 0-8 
urine (mg) 
Observed SA corrected 





41 M 23 62 No 250 5.52 1.45 8.15 211.8 0.038
42 F 38 86 Yes - 890 6.60 29.6 22.9 232.0 0.099
43 M 39 70 No - 520 5.78 4.0 8.7 231.7 0.037
44 M 45 70 No - 1260 6.25 7.9 7.2 227.2 0.032
45 M 48 86 No - 1110 5.78 3.4 8.1 235.5 0.034
46 F 48 79 No - 850 6.80 35.9 24.8 192.2 0.129
47 M 25 70 Yes - 2970 6.20 12.5 12.5 250.9 0.050
48 M 57 68 Yes - 890 6.75 11.7 1.8 179.7 0.010
49 M 34 N/K Yes - 2230 5.58 4.1 10.4 250.1 0.042
50 M 22 64 No - 365 6.60 15.5 8.8 221.3 0.040
51 F 44 50 No Tryptophan 1710 6.70 38.9 30.1 . 180.1 0.167
52 M 52 73 Yes — 1190 5.38 0.6 8.2 173.1 0.047
53 M 61 73 No - 610 5.77 7.5 12.3 202.9 0.061
54 M 44 71 No - 900 5.72 12.5 17.7 223.7 0.079
55 M 39 65 No Neonaclex 700 6.75 7.6 -2.3 166.1 -0.014
56 M 58 76 No - 890 5.88 4.4 8.2 228.0 0.036
57 M 24 67 No - 920 7.10 63.1 43.7 198.8 0.220
58 M 25 N/K Yes - 1650 5.30 0.0 8.0 239.1 0.033
59 M 29 73 No - 720 6.30 17.8 16.4 235.1 0.070
60 M 24 67 No - 490 6.10 6.5 7.8 269.2 0.029
61 M 40 67 No - 540 5.95 8.7 11.7 191.1 0.061
62 F 45 62 No - 450 5.07 0.0 14.7 51.2 0.287







































Amount recovered in 0-8 
urine (mg) 
Observed SA corrected 
SA to pH 6.2
hr
SUA
57 No Propranolol 480 5.20 2.5 11.0 41.5
63 Yes Beconase 860 6.90 20.5 6.9 207.3
73 Yes - 660 5.05 15.7 24.9 158.1
54 No - 990 6.45 29.8 25.9 90.8
57 Yes - 560 5.62 7.0 13.0 78.5
60 Yes OCS 200 5.30 0.6 8.6 28.2
57 No - 350 6.90 12.3 -1.3 50.1
60 No - 170 5.95 4.8 7.8 42.9
49 No ocs 340 5.62 7.9 13.9 61.4
53 Yes ocs 300 6.30 35.9 34.5 89.6
73 No - 655 5.40 6.6 14.1 444.7
83 No - 500 5.70 2.0 7.4 224.3
70 No - 430 5.75 8.0 13.0 207.2
6L No Vitamin B 950 6.75 73.4 63.5 200.1
70 No - 650 6.20 15.2 15.2 197.0
61 No - 235 5.45 2.6 9.8 169.9
87 . No Propanolol 950 . 6.40 2.4 -0.6 95.4
N/K No Palvadrine 1380 6.35 16.0 13.8 215.9
N/K No - 720 5.40 2.3 9.8 318.1
95 No - 800 5.72 8.4 13.6 255.7
78 No - 960 6.70 19.1 10.3 244.1
57 Yes - 660 5.95 36.1 39.2 195.5
75 Yes Sodium chromoglycate 1040 63 0 3.2 -7.9 295.9






































Amount recovered in 0-8 
urine (mg) 
Observed SA corrected 
SA to pH 6.2
hr
SUA
46 No - 610 5.45 4.8 11.8 173.5
60 Yes - 4 O 7.15 50.6 29.6 201.6
N/K No - 670 6.50 21 ..8 17.1 222.0
71 No - 1290 6.45 15.5 11.6 181.3
64 Yes - 800 6.50 23.2 18.5 200.8
60 Yes - 480 5.70 10.6 16.0 246.2
70 Yes - 790 5.40 3.7 11.2 240.6
N/K No - 1440 5.40 6.2 13.7 240.9
54 No - 1240 6.10 38.6 39.9 209.6
70 No - 1040 6.02 13.3 15.6 219.2
55 No - 790 6.45 36.4 32.5 191.7
77 No - 540 6.65 39.2 31.5 191.5
76 No Ventolin, Becotide, 
Intal
815 5.80 11.4 15.9 199.1
70 No - 370 6.60 46.6 39.9 122.7
79 No - 440 5.79 8.8 13.4 280.1
75 Yes - 440 6.75 59.6 49 .7 225.7
78 No - 890 5.55 10.1 16.6 199.5
84 No - 490 5.82 14.6 18.9 242.1
89 Yes - 330 5.30 4.1 12.1 226.7
89 Yes - 1790 6.05 11.3 13.2 265.6
78 Yes - 730 5.30 6.3 14.3 209.6
102 No - 2270 5.15 2.6 11.3 273.9
97 Yes - 1120 6.75 23.2 13.3 167.2
























Body Other drugs taken Urine Urine Amount recovered in 0-8 hr
Weight Smoker concomitantly Volume pH urine (mg)
(kg) with aspirin (mis) Observed SA corrected SUA 
SA to pH 6.2
57 No - 390 6.01 9.0 11.4 165.75
77 No - 590 6.74 8.2 -1.5 72.9
64 No OCS 360 6.35 10.8 8.6 316.5
60 No - 290 6.78 8.5 -2.1 67.9
60 No - 310 6.50 19.1 14.4 345.6
49 No - 270 7.19 47.3 26.3 159.1
57 No - 280 5.38 8.2 15.8 179.9
75 No - 470 5.26 4.75 12.95 160.1
57 No -  • 350 6.28 12.95 11.85 311.2
74 No — 250 5.86 7.15 11.15 113.0
63 Yes Minocin 200 7.28 31.0 5.5 92.5
N/K No - 540 5.87 7.5 11.4 90.9
N/K Yes - 330 6.70 7.2 -1.6 129.3
70 No - 850 7.52 32.3 -3.0 144.1
56 No Vitamin 550 7.33 39.3 11.9 134.5
70 No 370 5.65 0.0 5.8 120.8
53 No - 260 7.42 30.5 -0.5 111.0
61 No - 410 6.94 10.8 -3.9 133.2
57 Yes - 250 8.02 34.2 -29.9 101.6
68 No - 890 6.46 34.7 30.7 227.4
76 No - 430 6.27 15.6 14.6 210.7
54 No OCS 650 6.49 29.8 25.2 206.7
















Amount recovered in 0-8 
urine (mg) 
Observed SA corrected 





135 M 18 70 No 140 7.34 8.9 -18.9 .88.8 -0.213
136 M 20 67 No - 400 6.31 16.6 15.0 229.2 0.065
137 M 20 92 No - 540 6.67 18.3 10.2 240.3 0.042
138 F 18 63 No - 380 6.64 37.1 29.6 211.5 0.140
139 M 19 79 Yes - 300 6.62 10.0 2.9 220.6 0.013
140 M 18 63 No Oxytetracyclin 420 5.85 12.2 16.3 184.2 0.088
141 F 22 62 No - 1580 7.12 60.2 39.2 217.2 0.180
142 M 23 72 No - 860 7.00 9.2 -7.2 212.4 -0.034
143 F 27 53 No - 1120 6.29 19.8 18.5 198.2 0.093
144 F 41 70 No - 250 5.09 2.4 11.4 200.6 0.057
145 F 25 63 No OCS 200 5.63 4.4 10.3 199.7 0.052 j
146 F 27 66 No - 570 6.16 19.5 20.1 197.8 .0.102 1
147 F 20 57 No ocs 490 5.71 16.4 21.7 132.4 0.164 1
148 F 39 47 Yes - 1350 6.34 38.8 36.8 222.75 0.165
149 M 53 N/K No - 610 5.5 7.4 14.3 226.6 0.063
150 M N/K N/K N/K N/K 560 5.9 12.5 16.1 190.1 0.085
APPENDIX la. Repeat aspirin study: Total amounts of aspirin metabolites excreted in 0 - 8 hr urine following 2 separate 
























7 17 270 5.70 5.7 11.1 226.1 240 6.59 32.6 26.1 185.3
10 27 685 6.47 24.8 20.6 199.6 770 6.76 68.3 58.2 191.0
22 17 305 5.35 5.4 13.2 144.8 320 6.81 73.7 62.4 168.7
24 26 710 7.30 86.1 59.9 96.0 330 5.59 13.0 19.2 140.0
27 16 355 6.43 16.95 13.45 210.6 390 6.27 17.9 16.9 221.5
32 15 155 5.97 3.8 6.6 206.3 880 6.43 3.6 0.1 81.3
41 7 250 5.52 1.45 8.15 211.8 2450 6.74 17.6 7.9 224.5
43 7 520 5.78 4.00 8.7 231.7 820 5.85 5.2 9.3 240.0
55 7 700 6.75 7.6 -2.3 166.1 700 6.77 9.7 -0.7 205.8
59 7 490 6.10 6.5 7.8 235.1 390 5.68 8.7 14.2 109.8
66 19 660 5.05 15.7 24.9 158.1 600 4.97 3.5 12.95 245.7
84 18 1040 6.80 3.2 -7.9 244.1 1000 6.97 43.7 28.2 252.0




APPENDIX 2. Details of volunteers in paracetamol study and the total amounts of paracetamol metabolites excreted in 


















+ PG + PS
1 F 27 48 No 140 414.5 515.8 8.5 938.8
2 ' F 43 52 Yes - 290 715.4 236.8 14.6 966.8
3 M 37 68 No - 1240 599.5 236.2 29.7 865.4
4 M 29 65 Yes - 2330 433.4 224.8 30.5 688.7
5 M 44 87 No - 1000 323.0 257.0 35.9 615.9
6 F 26 46 No - 200 433.3 240.9 6.8 681.0
7 M 37 76 Yes - 510 504.1 348.3 20.1 872.4
8 F 47 78 Yes - 1170 420.0 267.3 30.5 717.8
9 M 41 84 No - 1150 286.3 159.3 22.5 468.1
10 F 40 51 No Fe SO 490 238.9 118.3 11.6 368.8
11 M 36 86 Yes c 4 1360 261.1 182.9 13.4 457.4
12 F 31 61 No Anafranil 1020 458.5 93.3 14.9 566.7
13 M 43 67 Yes - 210 271.4 131.5 11.1 414.0
14 M 19 79 No - 1130 533.4 55.9 16.5 605.7
15 M 22 N/K No - 2050 317.7 71.7 11.1 400.5
16 M 34 79 No - 1850 371.9 86.0 8.4 466.3
17 M 59 76 Yes - 890 396.9 122.4 17.5 538.8
18 M 25 48 No - 1320 362.3 142.6 17.3 522.7





Body Other drugs taken Urine Amount excreted in 0-8 hr urine (mg)
Volunteer Sex Age Weight Smoker concomitantly with Volume
(yrs) (kg) paracetamol (mis) PG PS P P + PG + PS
20 F 57 59 No - 410 302.0 168.9 17.8 488.7
21 M 25 N/K No - 1550 317.8 71.3 17.4 406.5
22 M 54 79 No Atenolol 510 194.8 90.0 13.1 297.9
23 F 24 N/K No OCS 580 346.0 152.0 19.5 517.5
24 M 20 73 No - 2100 355.9 200.5 36.8 593.2
25 M 46 70 No - 2060 443.9 167.9 23.7 635.5
26 F 27 54 No - 1030 526.3 250.3 20.4 797.0
27 F 25 67 No - 700 410.2 177.8 14.5 602.5
28 M 36 78 No - 570 471.7 157.9 14.0 643.6
29 M 23 73 No - 670 301.2 135.7 16.8 453.7
30 F 31 N/K No - 810 518.8 203.7 33.6 756.1
31 M 36 71 No - 200 461.8 238.8 13.4 714.0
32 M 39 64 Yes - 380 301.0 245.5 17.2 563.7
33 M 38 82 No - 300 404.25 262.0 15.0 681.25
34 M 39 N/K Yes - 980 444.4 392.0 25.7 862.1
35 M 38 73 No - 700 587.7 162.4 21.0 771.1
36 M 42 74 No Diuretic or blocker 
or placebo
1130 431.1 284.2 17.6 732.9
37 F 47 64 No Diuretic 310 388.0 276.2 24.9 689.1
38 M 47 87 No - 340 268.4 292.6 21.8 582.8
39 F 27 N/K No OCS 240 516.5 93.0 11.8 621.3
40 M 45 N/K No Amitryphiline; 
Nitrazolam























Body Other drugs taken Urine Amount excreted in 0-8 hr urine (mg)
Weight Smoker concomitantly with Volume
(kg) paracetamol (mis) PG PS P P + PG + PS
76 No - 540
58 No - 450
N/K No - 750
72 No Clonidene 1210
N/K No - 660
71 No - 1420
83 No - 1110
74 No - 670
70 No - 580
75 No - 370
102 No 610
65 No - 335
78 No - 440
84 Yes - 1395
76 No OCS 620
73 No Bendrofluazide, 
Sanomigran
1335
54 No - 1000
85 No - 1320
87 No - 505
72 No Prednisolone 1450
61 No OCS 385
N/K No — 660
509.2 161.5 14.2 684.9
294.1 233.3 30.2 557.6
320.6 180.4 12.3 513.3
346.1 197.2 20.1 563.4
345.5 173.9 18.8 538.2
474.3 182.5 24.5 681.3
505.0 245.9 26.4 776.3
376.9 380.2 26.5 783.6
370.3 289.4 20.5 680.2
587.0 205.2 31.8 824.0
526.7 221.7 24.8 773.2
419.1 288.1 26.8 734.0
362.8 290.2 7.3 660.3
263.6 283.2 44.8 591.6
407.3 114.1 9.9 531.3
571.4 200.2 18.9 790.5
639.0 244.0 26.3 909.3
462.7 215.8 24.4 702.9
406.0 177.0 12.9 595.9
395.1 289.3 24.0 708.4
418.9 293.0 3.7 715.6






















+ PG + PS
63 M 41 72 No 710 406.5 264.1 23.2 693.8
64 M 43 76 Yes - 180 457.0 330.75 12.3 800.05
65 M 19 95 Yes - 390 453.8 175.9 18.8 648.5
66 F 36 N/K No Ibuoprofen 570 523.8 247.4 12.6 783.8
67 F 40 95 Yes - 950 570.5 560.5 21.0 1152.0
68 F 21 51 No OCS 235 290.5 96.7 14.6 401.8
69 F 56 49 Yes — 560 418.9 312.5 22.6 754.0
70 M 25 59 Yes — 425 438.4 125.8 27.0 591.2
71 M 47 95 No - 680 278.8 318.6 22.5 619.9
72 M 23 73 No ■ - 840 470.4 185.6 29.5 685.5
73 M 27 70 Yes - 2330 475.3 143.3 25.9 644.5
74 M 20 74 No - 780 481.3 256.6 40.0 778.0
75 M 54 83 Yes - 740 558.7 199.8 20.9 779.4
76 F 46 51 No - 630 323.1 272.3 22.1 617.5
77 M 62 64 No - 935 207.1 233.75 46.2 487.05
78 M 18 N/K No - 360 434.5 144.0 26.7 605.2
79 M 28 N/K Yes - 1310 446.7 243.7 24.4 268.1
80 M 22 N/K Yes - 630 362.2 277.2 26.0 665.4
81 M 44 87 No Tenormin,Apresoline 690 372.6 287.4 29.0 689.0
82 M
_______ t_______
53 94 No Tenormin, Histamet, 
Buprofen
840 494.3 160.4 17.4 672.1
Appendix 2 continued
Body Other drugs taken Urine Amount excreted in 0-8 hr urine (mg)
Volunteer Sex Age Weight Smoker concomitantly with Volume
(yrs) (kg) paracetamol (mis) PG PS P P + PG + PS
83 M 55 67 No Metoprolol 470 427.5 280.1 27.3 734.9
84 M 23 73 No - ■ 460 285.0 309.8 20.7 615.5
85 F 26 58 No - 620 479.9 257.3 22.0 759.2
86 M 24 80 Yes - 560 314.7 178.6 11.7 505.0
87 F 28 54 No OCS 350 386.7 190.2 27.9 604.8
88 F 32 70 No ocs 450 607.7 172.6 18.9 799.2
89 M 20 54 No - 500 532.5 330.5 17.8 880.8
90 M 44 67 Yes - 245 517.9 115.5 13.2 646.6
91 F 45 64 No - 190 417.3 262.4 8.9 688.6
92 F 26 60 No ocs 660 610.2 JL88.8 24.5 823.5
93 F 24 67 No ocs 900 485.1 211.5 27.2 723.8
94 M 27 60 No - 1000 572.5 248.5 32.4 853.4
95 F 39 47 Yes - 1050 573.8 ' 351.7 60.5 986.0
96 M 36 60.5 Yes - 820 319.8 170.1 26.4 516.3
97 M • 25 69 No - 500 664.0 238.5 14.9 917.4
98 F 24 70 No ocs 250 551.2 130.1 21.3 702.6






















Volunteer details for the oral contraceptive study and the 0 - 24 hour urinary excretion of endogenous estradiol and 






















0-24 hr urinary 
excretion (ng)
E2 E2G E2S
20 75 21 No 240 85.8 1245.0 445.2
20 61 Ovranette 10 months 16 Yes - 17.8 800 167.8 364.9 33.£
21 44 Ovranette 3% years 19 Yes - 21.7 1590 120.8 91.5 9.2
21 64 - - 16 No - 108.7 1250 188.0 2584.4 1194.2
21 65 Norimin 4 years 19 No - 17.4 995 117.4 363.8 36.£
21 60 Logynon 3 years 19 No - 14.2 570 97.2 201.2 N/E
19 60 Brevinor 14 months 16 Yes - 21.1 1180 76.5 235.3 42. £
21 56 - - 38 No - 256.2 2240 342.7 3577.3 2203.€
20 57 Binovum 9 months 18 No - 26.3 725 164.9 318.7 N/E
22 63 Ovranette 1 year 18 No - 18.1 1030 56.7 307.0 42.1
22 61 Trinordial 6 months 18 No - 20.2 600 78.45 181.5 13.4
22 62 Logynon 1 year 20 No - 17.3 690 149.9 449.2 5.2
20 53 Marvelon 10 months 18 No - 15.0 720 149.7 172.5 N/E
20 69 Binovum 1 year 18 No - 17.1 820 105.5 448.2 178.2
19 63 Ovranette 21 months 19 No - 18.3 740 112.1 478.1 N/E
19 50 Trinordial 8 months 19 No - 26.5 620 126.7 357.2 N/E
20 61 Microgynon 1Vz years 18 Yes - 23.5 1400 137.6 262.2 96.1
20 66 Logynon 3 years 17 Yes - 17.1 690 75.2 147.4 N/E
19 62 Ovranette 2 years 20 No - 17.8 1320 121.2 466.5 105.£


























0-24 hr urinary 
excretion (ng)
E2 e2g E25
21 24 53 Trinordial 1 year 19 No 15.7 2220 162.5 2752.6 3839.2
22 22 72 - - 18 No - 51.1 2230 132.7 2136.8 584.7
23 22 63 - — 21 No Atenolol 208.5 1120 317.1 3932.6 1082.8
24 32 57 - - 21 No - 148.9 930 377.1 3442.8 1244.1
25 28 53 Microgynon 5 years 22 No - 20.0 1450 66. 5 1555.1 455.9
26 21 61 Microgynon 3 years 20 No - 22.2 1400 283.2 434.0 266.7
27 19 54 - - 20 No - 136.0 960 251.4 1673.6 549.5
28 21 57 Logynon 3 years 19 No - 15.1 570 122.7 233.1 N/D
29 21 75 Ovranette 5 years 20 No - 26.0 1330 257.5 795.1 285.6
30 22 57 Microgynon 4 years 19 No - 17.3 1150 183.5 442.6 26.4!
31 21 66 Ovysman 2 years 19 No - 14.3 1050 65.5 476.4 62.4
32 19, 55 Logynon 2 years 20 No - 18.6 1380 165.6 289.4 37.5
33 22 48 Brevinor 2 years 20 No - 16.7 1690 109.2 298.4 139.4
34 18 55 . Trinovium 7 months 19 No - 15.6 720 91.8 101.8 2.7
35 19 55 Logynon 3 years 18 No - - 1580 130.0 226.9 N/D
36 19 57 Logynon 2 years 20 No - 19.3 850 135.8 309.7 N/D
37 19 62 Trinordial 1 year 19 Yes - 19.8 1480 217.1 304.5 94.0
38 19 66 Logynon 1 year 19 No - 17.5 700 116.0 127.0 N/D
39 24 69 Logynon 8 years 17 No - - 1470 177.7 861.9 85.0
40 25 68 Microgynon 8 years 21 No - 21.4 1460 298.9 243.2 N/D
41 20 63 Ovysmen 15 months 19 No - 14.4 1120 80.8 187.7 164.2
43 21 57 Ovranette 3 years 20 No - 18.8 1790 98.8 689.9 191.2
44 25 53 - - 20 Yes - 69.7 3360 2994.4 5484.9 1987.1
45 28 67 Brevinor 6 months 21 No - 17.4 2560 243.3 567.3 52.2
46 32 68 Logynon 14 years 18 No - 15.1 1700 1797 1359.7 238.6
212.
APPENDIX 4. The 0 - 8  hour and the 8 - 24 hour urinary excretion of 
paracetamol and its major metabolites following an oral 
dose of paracetamol (50 mg/kg) in the female rat. (Urinary 
excretion expressed as % of administered dose).
0
PG




8 - 24 hr urine
EE2~Treated Rats 
IT 23.5 65.3 2.6
2T 13.1 45.7 1.2 5.6 21.2 0.8
3T 13.4 33.6 1.8 1.4 12.9 3.2
4T 16.0 44.4 1.7 5.9 20.6 0.6
5T 15.9 50.6 1.7 0.9 12.3 2.8
6T 10.2 37.9 1.5 1.5 6.9 0.5
7T 25.5 54.7 2.6 2.5 8.1 0.6
8T 24.2 62.2 3.8 0.7 6.4 1.4
9T 11.1 35.5 1.5 1.5 5.2 0.2
10T 6.3 22.9 1.0 2.9 12.0 0.9
11T 19.2 40.9 2.0 6.0 20.7 0.6
12T 13.6 48.1 2.2 2.5 9.2 1.0
Control Rats 
1C 18.4 51.3 2.4 2.3 15.6 2.1
2C 13.7 65.6 2.0 2.2 14.2 0.4
3C 13.3 48.9 2.1 3.2 19.5 0.6
4C 9.6 37.2 1.5 4.8 29.9 0.8
5C 5.8 28.9 1.7 4.2 37.7 0.7
6C 9.9 32.0 1.9 0.9 16.4 3.9
7C 12.5 42.9 1.4 0.8 12.9 2.5
8C 8.4 41.2 1.5 2.3 14.1 1.0
9C 9.8 41.6 1.6 3.0 16.0 1.1
10C 12.3 38.2 2.3 3.2 11.9 1.1
11C 15.1 46.1 1.9 2.3 17.0 0.7
12C 4.7 17.9 1.6 5.0 23.7 0.5
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APPENDIX 5. 24 hour urinary excretion of total estradiol and 24 hour 
estradiol content of several tissues following IV 
administration of ^C-E^ (26.6 g; 5.07 Ci/kg) in the 
female rat.
Total Tissue radioactive content 24 hours
RAT Radioactivity ^












IT 27.80 1.96 29.06 61.23 26.96
2T 39.62 1.79 29.00 134.49 23.79
3T 28.67 3.36 38.07 65.50 251.25
4T 37.82 2.05 13.30 69.06 484.36
5T 34.93 2.37 33.89 103.04 7.94
Control Rats
1C 20.92 3.01 118.72 84.44 21.24
2C 18.73 2.60 45.59 120.91 21.96
3C 16.47 2.45 51.75 100.07 19.83
4C 19.87 3.21 41.46 169.77 94.29
5C 22.48 2.93 53.88 105.32 -
